Coronary artery disease causes severe disability and more death than any other disease in affluent societies. Medical conditions associated with this disease are angina, ischaemia, unstable angina, myocardial infarction, arrhythmias, heart failure, and sudden death.

In recent years, interventional cardiology, particularly percutaneous coronary intervention, has progressed dramatically and undergone incredible evolution. In many countries, numbers of percutaneous coronary procedures now equal or exceed bypass surgery. Although coronary intervention has held centre stage, major inroads in non-coronary percutaneous intervention have been made.

Much of the breathtaking momentum seen in interventional cardiology in recent years has been captured in this highly informative and well illustrated ABC of Interventional Cardiology. It will help the reader to make decisions on cardiac diagnosis and appropriate care, and to advise patients on the benefits that percutaneous intervention can offer.

Chapters include:
- Pathophysiology and investigation of coronary artery disease
- Percutaneous coronary intervention
- Chronic stable angina: treatment options
- Acute coronary syndrome
- Percutaneous coronary intervention: cardiogenic shock
- Interventional pharmacotherapy
- Non-coronary percutaneous intervention
- New developments in percutaneous coronary intervention
- Percutaneous interventional electrophysiology
- Implantable devices for treating tachyarrhythmias
- Interventional paediatric cardiology

Broad, and sometimes complex, aspects of interventional cardiology are presented in a clear, concise, and balanced manner. This easy to read text, supplemented by numerous images and graphics, will appeal to a broad readership, including medical students, family doctors, physicians, and cardiologists.
ABC OF
INTERVENTIONAL CARDIOLOGY
For Lisa, Alexander, and Frances
ABC OF INTERVENTIONAL CARDIOLOGY

Edited by

EVER D GRECH
Consultant Cardiologist, South Yorkshire Cardiothoracic Centre,
Northern General Hospital, Sheffield, UK
# Contents

*Contributors* vi
*Preface* vii
*Acknowledgements* viii

1. **Pathophysiology and investigation of coronary artery disease**
   *Ever D Grech*

2. **Percutaneous coronary intervention. I: History and Development**
   *Ever D Grech*

3. **Percutaneous coronary intervention. II: The procedure**
   *Ever D Grech*

4. **Chronic stable angina: treatment options**
   *Lawrence O'Toole, Ever D Grech*

5. **Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction**
   *Ever D Grech, David R Ramsdale*

6. **Acute coronary syndrome: ST segment elevation myocardial infarction**
   *Ever D Grech, David R Ramsdale*

7. **Percutaneous coronary intervention: cardiogenic shock**
   *John Ducas, Ever D Grech*

8. **Interventional pharmacotherapy**
   *Roger Philipp, Ever D Grech*

9. **Non-coronary percutaneous intervention**
   *Ever D Grech*

10. **New developments in percutaneous coronary intervention**
    *Julian Gunn, Ever D Grech, David Crossman, David Cumberland*

11. **Percutaneous interventional electrophysiology**
    *Gerry C Kaye*

12. **Implantable devices for treating tachyarrhythmias**
    *Timothy Houghton, Gerry C Kaye*

13. **Interventional paediatric cardiology**
    *Kevin P Walsh*

*Index* 49
Contributors

David Crossman
Professor of Clinical Cardiology, Cardiovascular Research Group, Clinical Sciences Centre, Northern General Hospital, Sheffield

David Cumberland
Consultant Cardiovascular Interventionist, Ampang Puteri Specialist Hospital, Kuala Lumpur, Malaysia

John Ducas
Consultant Cardiologist, Health Sciences Centre and St Boniface Hospital, Winnipeg, Manitoba and Associate Professor, University of Manitoba, Winnipeg, Canada

Ever D Grech
Consultant Cardiologist, South Yorkshire Cardiothoracic Centre, Northern General Hospital, Sheffield, UK

Julian Gunn
Senior Lecturer and Honorary Consultant Cardiologist, Cardiovascular Research Group, Clinical Sciences Centre, Northern General Hospital, Sheffield

Timothy Houghton
Registrar in Cardiology, Hull and East Yorkshire Trust, Castle Hill Hospital, Hull

Gerry C Kaye
Consultant Cardiologist, Hull and East Yorkshire Trust, Castle Hill Hospital, Hull

Laurence O’Toole
Consultant Cardiologist and Physician, Royal Hallamshire Hospital, Sheffield

Roger Philipp
Fellow in Interventional Cardiology, Health Sciences Centre and St Boniface Hospital, Winnipeg, Manitoba, Canada

David R Ramsdale
Consultant Cardiologist, Cardiothoracic Centre, Liverpool

Kevin P Walsh
Consultant Paediatric Cardiologist, Our Lady’s Hospital for Sick Children, Crumlin, Dublin, Republic of Ireland
Preface

It is only 26 years since the first percutaneous transluminal coronary angioplasty (PTCA) was carried out by the pioneering Swiss radiologist, Andreas Greuntzig, heralding the dawn of interventional cardiology. In this short time, interventional cardiology has overcome many limitations and undergone major evolutionary changes—most notably the development of the coronary stent. Worldwide, many thousands of patients now safely undergo percutaneous coronary intervention every day, and the numbers continue to grow. In many countries, the numbers are similar to, or exceed, bypass surgical procedures.

Although, at first, PTCA was indicated only as treatment for chronic stable angina caused by a discrete lesion in a single vessel, this has now progressed to encompass multi-lesion and multi-vessel disease. Moreover, percutaneous intervention is now becoming widely used in the management of unstable angina and acute myocardial infarction with definite benefits in terms of morbidity and mortality. The effectiveness and safety of these procedures has undoubtedly been enhanced by the adjunctive use of new anti-platelet and antithrombotic agents.

As the indications increase and more patients are treated, so inevitably do the demands on healthcare budgets. Undoubtedly, percutaneous intervention is expensive. However, this burden must be weighed against bypass surgery, which is even more costly, and multi-drug treatment—which would be required over many years.

Although percutaneous coronary intervention has held centre stage in cardiology, major in-roads have also been made in non-coronary areas. Transcatheter valvuloplasty, ethanol septal ablation and closure devices have become effective and safe alternatives to surgery, as have paediatric interventional procedures. A greater understanding of cardiac electrophysiology has led to important advances in the treatment of arrhythmias, and implantable cardioverter defibrillators are benefiting ever larger numbers of patients.

Where are we heading? This is perhaps the biggest question in the minds of many interventional cardiologists. New technology generated by industry and new techniques coupled with high levels of expertise are fuelling advances in almost all areas of interventional cardiology. As drug-eluting stents address the Achilles’ heel of angioplasty and stenting—restenosis—the huge increase in percutaneous coronary procedures seen over recent years is likely to increase even further, and will probably be double the rate of bypass surgery within a decade.

In writing and editing this book, I have endeavoured to present broad (and sometimes complex) aspects of interventional cardiology in a clear, concise and balanced manner. To this end, an easy-to-read style of text, avoiding jargon and exhaustive detail, has been used supplemented with many images and graphics.

EVER D GRECH
Sheffield, July 2003
Acknowledgements

I have many people to thank for helping me develop and produce this book. I am very grateful to my coauthors who have all willingly contributed their time and expertise. I would also like to recognise the positive efforts and invaluable assistance of the British Medical Journal editors and illustrators. These include Trish Groves, Mary Banks, Eleanor Lines, Greg Cotton, and Naomi Wilkinson.

Finally, my enduring gratitude goes to my family for their unfailing encouragement, patience, and love.
1 Pathophysiology and investigation of coronary artery disease

Ever D Grech

In affluent societies, coronary artery disease causes severe disability and more death than any other disease, including cancer. It manifests as angina, silent ischaemia, unstable angina, myocardial infarction, arrhythmias, heart failure, and sudden death.

Pathophysiology

Coronary artery disease is almost always due to atheromatous narrowing and subsequent occlusion of the vessel. Early atheroma (from the Greek athera (porridge) and oma (lump)) is present from young adulthood onwards. A mature plaque is composed of two constituents, each associated with a particular cell population. The lipid core is mainly released from necrotic “foam cells”—monocyte derived macrophages, which migrate into the intima and ingest lipids. The connective tissue matrix is derived from smooth muscle cells, which migrate from the media into the intima, where they proliferate and change their phenotype to form a fibrous capsule around the lipid core.

When a plaque produces a > 50% diameter stenosis (or > 75% reduction in cross sectional area), reduced blood flow through the coronary artery during exertion may lead to angina. Acute coronary events usually arise when thrombus formation follows disruption of a plaque. Intimal injury causes denudation of the thrombogenic matrix or lipid pool and triggers thrombus formation. In acute myocardial infarction, occlusion is more complete than in unstable angina, where arterial occlusion is usually subtotal. Downstream embolism of thrombus may also produce microinfarcts.

Investigations

Patients presenting with chest pain may be identified as having definite or possible angina from their history alone. In the former group, risk factor assessment should be undertaken, both to guide diagnosis and because modification of some associated risk factors can reduce cardiovascular events and mortality. A blood count, biochemical screen, and thyroid function tests may identify extra factors underlying the onset of angina. Initial drug treatment should include aspirin, a β blocker, and a nitrate. Antihypertensive and lipid lowering drugs may also be given, in conjunction with advice on lifestyle and risk factor modification.

All patients should be referred to a cardiologist to clarify the diagnosis, optimise drug treatment, and assess the need and suitability for revascularisation (which can improve both symptoms and prognosis). Patients should be advised to seek urgent medical help if their symptoms occur at rest or on minimal exertion and if they persist for more than 10 minutes after sublingual nitrate has been taken, as these may herald the onset of an acute coronary syndrome.

Priorities for cardiology referral

- Recent onset of symptoms
- Rapidly progressive symptoms
- Possible aortic stenosis
- Threatened employment
- Severe symptoms (minimal exertion or nocturnal angina)
- Angina refractory to medical treatment
- Age
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Fibrinogen
- Renin
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Hypertriglyceridaemia
- Microalbuminuria
- Lp(a) lipoprotein
- Fibrinogen
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Hypertriglyceridaemia
- Microalbuminuria
- Lp(a) lipoprotein
- Fibrinogen
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin

Cardiovascular risk factors

Non-modifiable risk factors
- Positive family history
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
- Sedentary lifestyle
- Diabetes
- Excessive alcohol intake
- Lp(a) lipoprotein
- Uric acid
- Renin
- Hypertriglyceridaemia
- Microalbuminuria
- Hyperhomocysteinaemia
- C reactive protein
- Male sex
- Male sex
- Hypertension
- Smoking
Non-invasive investigations

Electrocardiography
An abnormal electrocardiogram increases the suspicion of significant coronary disease, but a normal result does not exclude it.

Chest x-ray
Patients with angina and no prior history of cardiac disease usually have a normal chest x-ray film.

Exercise electrocardiography
This is the most widely used test in evaluating patients with suspected angina. It is generally safe (risk ratio of major adverse events 1 in 2500, and of mortality 1 in 10 000) and provides diagnostic as well as prognostic information. The average sensitivity and specificity is 75%. The test is interpreted in terms of achieved workload, symptoms, and electrocardiographic response. A 1 mm depression in the horizontal ST segment is the usual cut-off point for significant ischaemia. Poor exercise capacity, an abnormal blood pressure response, and profound ischaemic electrocardiographic changes are associated with a poor prognosis.

Main end points for exercise electrocardiography
- Target heart rate achieved (>85% of maximum predicted heart rate)
- ST segment depression > 1 mm (downsloping or planar depression of greater predictive value than upsloping depression)
- Slow ST recovery to normal (> 5 minutes)
- Decrease in systolic blood pressure > 20 mm Hg
- Increase in diastolic blood pressure > 15 mm Hg
- Progressive ST segment elevation or depression
- ST segment depression > 3 mm without pain
- Arrhythmias (atrial fibrillation, ventricular tachycardia)

Features indicative of a strongly positive exercise test
- Exercise limited by angina to < 5 minutes of Bruce protocol
- Failure of systolic blood pressure to increase > 10 mm Hg, or fall with evidence of ischaemia
- Widespread marked ST segment depression > 3 mm
- Prolonged recovery time of ST changes (>6 minutes)
- Development of ventricular tachycardia
- ST elevation in absence of prior myocardial infarction

Stress echocardiography
Stress induced impairment of myocardial contraction is a sensitive marker of ischaemia and precedes electrocardiographic changes and angina. Cross sectional echocardiography can be used to evaluate regional and global left ventricular impairment during ischaemia, which can be induced by exercise or an intravenous infusion of drugs that increase myocardial contraction and heart rate (such as dobutamine) or dilate coronary arteriicles (such as dipyridamole or adenosine). The test has a higher sensitivity and specificity than exercise electrocardiography and is useful in patients whose physical condition limits exercise.

Radionuclide myocardial perfusion imaging
Thallium-201 or technetium-99m (99mTc-sestamibi, 99mTc-tetrofosmin) is injected intravenously at peak stress, and its myocardial distribution relates to coronary flow. Images are acquired with a gamma camera. This test can distinguish between reversible and irreversible ischaemia (the latter signifying infarcted tissue). Although it is expensive and requires specialised equipment, it is useful in patients whose exercise test is non-diagnostic or whose exercise ability is limited.
A multigated acquisition (MUGA) scan assesses left ventricular function and can reveal salvageable myocardium in patients with chronic coronary artery disease. It can be performed with either thallium scintigraphy at rest or metabolic imaging with fluorodeoxyglucose by means of either positron emission tomography (PET) or single photon emission computed tomography (SPECT).

Invasive investigations

Coronary angiography

The only absolute way to evaluate coronary artery disease is by angiography. It is usually performed as part of cardiac catheterisation, which includes left ventricular angiography and haemodynamic measurements, providing a more complete evaluation of an individual’s cardiac status. Cardiac catheterisation is safely performed as a day case procedure.

Patients must be fully informed of the purpose of the procedure as well as its risks and limitations. Major complications, though rare in experienced hands, include death (risk ratio 1 in 1400), stroke (1 in 1000), coronary artery dissection (1 in 1000), and arterial access complications (1 in 500). Risks depend on the individual patient, and predictors include age, coronary anatomy (such as severe left main stem disease), impaired left ventricular function, valvar heart disease, the clinical setting, and non-cardiac disease. The commonest complications are transient or minor and include arterial access bleeding and haematoma, pseudoaneurysm, arrhythmias, reactions to the contrast medium, and vagal reactions (during sheath insertion or removal).

Before the procedure, patients usually fast and may be given a sedative. Although a local anaesthetic is used, arterial access (femoral, brachial, or radial) may be mildly uncomfortable. Patients do not usually feel the catheters once they are inside the arteries. Transient angina may occur during injection of contrast medium, usually because of a severely diseased artery. Patients should be warned that, during left ventricular angiography, the large volume of contrast medium may cause a transient hot flush and a strange awareness of urinary incontinence (and can be reassured that this does not actually happen). Modern contrast agents rarely cause nausea and vomiting.

Insertion of an arterial sheath with a haemostatic valve minimises blood loss and allows catheter exchange. Three types of catheter, which come in a variety of shapes and diameters, are commonly used. Two have a single hole at the end and are designed to facilitate controlled engagement of the distal tip within the coronary artery ostium. Contrast medium is injected through the lumen of the catheter, and moving x-ray images are obtained and recorded. Other catheters may be used for graft angiography. The “pigtail” catheter has an end hole and several side holes and is passed across the aortic valve into the left ventricle. It allows injection of 30-40 ml of contrast medium.
over three to five seconds by a motorised pump, providing visualisation of left ventricular contraction over two to four cardiac cycles. Aortic and ventricular pressures are also recorded during the procedure.

**Intravascular ultrasound (IVUS)**

In contrast to angiography, which gives a two dimensional luminal silhouette with little information about the vessel wall, intravascular ultrasound provides a cross sectional, three dimensional image of the full circumference of the artery. It allows precise measurement of plaque length and thickness and minimum lumen diameter, and it may also characterise the plaque’s composition.

It is often used to clarify ambiguous angiographic findings and to identify wall dissections or thrombus. It is most useful during percutaneous coronary intervention, when target lesions can be assessed before, during, and after the procedure and at follow up. The procedure can also show that stents which seem to be well deployed on angiography are, in fact, suboptimally expanded. Its main limitations are the need for an operator experienced in its use and its expense; for these reasons it is not routinely used in many centres.

**Doppler flow wire and pressure wire**

Unlike angiography or intravascular ultrasound, the Doppler flow wire and pressure wire provide information on the physiological importance of a diseased coronary artery. They are usually used when angiography shows a stenosis that is of intermediate severity, or to determine the functional severity of a residual stenosis after percutaneous coronary intervention.

Intracoronary adenosine is used to dilate the distal coronary vessels in order to maximise coronary flow. The Doppler flow wire has a transducer at its tip, which is positioned beyond the stenosis to measure peak flow velocity. The pressure wire has a tip micrometer, which records arterial pressures proximal and distal to the stenosis.

The figure showing progression of atheromatous plaque from initial lesion is adapted with permission from Pepine CJ. *Am J Cardiol* 1998;82(suppl 10A):23-7S. Competing interests: None declared.

**Further reading**


Algorithm for management of suspected angina (PCI=percutaneous coronary intervention, CABG=coronary artery bypass grafting)
2 Percutaneous coronary intervention. I: History and development

Ever D Grech

The term “angina pectoris” was introduced by Heberden in 1772 to describe a syndrome characterised by a sensation of “strangling and anxiety” in the chest. Today, it is used for chest discomfort attributed to myocardial ischaemia arising from increased myocardial oxygen consumption. This is often induced by physical exertion, and the commonest aetiology is atheromatous coronary artery disease. The terms “chronic” and “stable” refer to anginal symptoms that have been present for at least several weeks without major deterioration. However, symptom variation occurs for several reasons, such as mental stress, ambient temperature, consumption of alcohol or large meals, and factors that may increase coronary tone such as drugs and hormonal change.

Classification

The Canadian Cardiovascular Society has provided a graded classification of angina which has become widely used. In clinical practice, it is important to describe accurately specific activities associated with angina in each patient. This should include walking distance, frequency, and duration of episodes.

History of myocardial revascularisation

In the management of chronic stable angina, there are two invasive techniques available for myocardial revascularisation: coronary artery bypass surgery and catheter attached devices. Although coronary artery bypass surgery was introduced in 1968, the first percutaneous transluminal coronary angioplasty was not performed until September 1977 by Andreas Gruentzig, a Swiss radiologist, in Zurich. The patient, 38 year old Adolph Bachman, underwent successful angioplasty to a left coronary artery lesion and remains well to this day. After the success of the operation, six patients were successfully treated with percutaneous transluminal coronary angioplasty in that year.

By today’s standards, the early procedures used cumbersome equipment: guide catheters were large and could easily traumatise the vessel, there were no guidewires, and balloon catheters were large with low burst pressures. As a result, the procedure was limited to patients with refractory angina, good left ventricular function, and a discrete, proximal, concentric, and non-calcific lesion in a single major coronary artery with no involvement of major side branches or angulations. Consequently, it was considered feasible in only 10% of all patients needing revascularisation.

Developments in percutaneous intervention

During 1977-86 guide catheters, guidewires, and balloon catheter technology were improved, with slimmer profiles and increased tolerance to high inflation pressures. As equipment improved and experience increased, so more complex lesions were treated and in more acute situations. Consequently, the procedure was limited to patients with refractory angina, good left ventricular function, and a discrete, proximal, concentric, and non-calcific lesion in a single major coronary artery with no involvement of major side branches or angulations. Consequently, it was considered feasible in only 10% of all patients needing revascularisation.

### Canadian Cardiovascular Society classification of angina

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>No angina during ordinary physical activity such as walking or climbing stairs</td>
</tr>
<tr>
<td>II</td>
<td>Angina during strenuous, rapid, or prolonged exertion</td>
</tr>
<tr>
<td>III</td>
<td>Marked limitation of ordinary physical activity</td>
</tr>
<tr>
<td>IV</td>
<td>Inability to carry out any physical activity without discomfort</td>
</tr>
</tbody>
</table>

### Developments in percutaneous coronary intervention

- **New stent designs and "smart" stents**
  - Pre-mounted
  - Increased flexibility and radial strength
  - Coated stents
  - Biodegradable stents
  - Drug or gene delivery stents
  - Radioactive stents

- **Brachytherapy**
  - γ radiation emission

- **New balloon designs**
  - Low profile
  - High inflation
  - Short or long balloons
  - Cutting balloons

- **Adjuvant pharmacotherapy**
  - ADP antagonists
  - Glycoprotein IIb/IIIa inhibitors
  - "Designer" drugs

Modern balloon catheter: its low profile facilitates lesion crossing, the flexible shaft allows tracking down tortuous vessels, and the balloon can be inflated to high pressures without distortion or rupture.
percutaneous transluminal coronary angioplasty can now be undertaken in about half of patients needing revascularisation (more in some countries), and it is also offered to high-risk patients for whom coronary artery bypass surgery may be considered too dangerous.

Although percutaneous transluminal coronary angioplasty causes plaque compression, the major change in lumen geometry is caused by fracturing and fissuring of the atheroma, extending into the vessel wall at variable depths and lengths. This injury accounts for the two major limitations of percutaneous transluminal coronary angioplasty—acute vessel closure and restenosis.

**Acute vessel closure**—This usually occurs within the first 24 hours of the procedure in about 3-5% of cases and follows vessel dissection, acute thrombus formation, or both. Important clinical consequences include myocardial infarction, emergency coronary artery bypass surgery, and death.

**Restenosis** occurring in the first six months after angioplasty is caused largely by smooth muscle cell proliferation and fibrointimal hyperplasia (often called neointimal proliferation), as well as elastic recoil. It is usually defined as a greater than 50% reduction in luminal diameter and has an incidence of 25-50% (higher after vein graft angioplasty). Further intervention may be indicated if angina and ischaemia recur.

**Drills, cutters, and lasers**

In the 1980s, two main developments aimed at limiting these problems emerged. The first were devices to remove plaque material, such as by rotational atherectomy, directional coronary atherectomy, transluminal extraction catheter, and excimer laser. By avoiding the vessel wall trauma seen during percutaneous transluminal coronary angioplasty, it was envisaged that both acute vessel closure and restenosis rates would be reduced.

However, early studies showed that, although acute closure rates were reduced, there was no significant reduction in restenosis. Moreover, these devices are expensive, not particularly user friendly, and have limited accessibility to more distal stenoses. As a result, they have now become niche tools used by relatively few interventionists. However, they may have an emerging role in reducing restenosis rates when used as adjunctive treatment before stenting (especially for large plaques) and in treating diffuse restenosis within a stent.

**Intracoronary stents**

The second development was the introduction of intracoronary stents deployed at the site of an atheromatous lesion. These were introduced in 1986 with the objective of tacking down dissection flaps and providing mechanical support. They also reduce elastic recoil and remodelling associated with restenosis.

The first large randomised studies conclusively showed the superiority of stenting over coronary angioplasty alone, both in clinical and angiographic outcomes, including a significant 30% reduction in restenosis rates. Surprisingly, this was not due to inhibition of neointimal proliferation—in fact stents may increase this response. The superiority of stenting is that the initial gain in luminal diameter is much greater than after angioplasty alone, mostly because of a reduction in elastic recoil. Although neointimal proliferation through the struts of the stent occurs, it is insufficient to cancel out the initial gain, leading to a larger lumen size and hence reduced restenosis. Maximising the vessel lumen is therefore a crucial mechanism for reducing restenosis. “Bigger is better” is the adage followed in this case.
Early stent problems
As a result of initial studies, stents were predominantly used either as “bail out” devices for acute vessel closure during coronary angioplasty (thus avoiding the need for immediate coronary artery bypass surgery) or for restenosis after angioplasty.

Thrombosis within a stent causing myocardial infarction and death was a major concern, and early aggressive anticoagulation to prevent this led to frequent complications from arterial puncture wounds as well as major systemic haemorrhage. These problems have now been overcome by the introduction of powerful antiplatelet drugs as a substitute for warfarin. The risk of thrombosis within a stent diminishes when the stent is lined with a new endothelial layer, and antiplatelet treatment can be stopped after a month. The recognition that suboptimal stent expansion is an important contributor to thrombosis in stents has led to the use of intravascular ultrasound to guide stent deployment and high pressure inflations to ensure complete stent expansion.

Current practice
A greater understanding of the pathophysiology of stent deployment, combined with the development of more flexible stents (which are pre-mounted on low-profile catheter balloons), has resulted in a massive worldwide increase in stent use, and they have become an essential component of coronary intervention. Low profile stents have also allowed “direct” stenting—that is, implanting a stent without the customary balloon dilatation—to become prevalent, with the advantages of economy, shorter procedure time, and less radiation from imaging. Most modern stents are expanded by balloon and made from stainless steel alloys. Their construction and design, metal thickness, surface coverage, and radial strength vary considerably.

Stents are now used in most coronary interventions and in a wide variety of clinical settings. They substantially increase procedural safety and success, and reduce the need for emergency coronary artery bypass surgery. Procedures involving stent deployment are now often referred to as percutaneous coronary interventions to distinguish them from conventional balloon angioplasty (percutaneous transluminal coronary angioplasty).

A major recent development has been the introduction of drug eluting stents (also referred to as “coated stents”), which reduce restenosis to very low rates. Their high cost currently limits their use, but, with increasing competition among manufacturers, they will probably become more affordable.

Competing interests: None declared.

The micrographs showing deep fissuring within a coronary artery wall atheroma and fragmented plaque tissue caused by coronary angioplasty were supplied by Kelly MacDonald, consultant histopathologist at St Boniface Hospital, Winnipeg, Canada.

Further reading

Unequivocal indications for use of coronary stents
- Acute or threatened vessel closure during angioplasty
- Primary reduction in restenosis in de novo lesions in arteries >3.0 mm in diameter
- Focal lesions in saphenous vein grafts
- Recanalised total chronic occlusions
- Primary treatment of acute coronary syndromes

Exponential increase in use of intracoronary stents since 1986. In 2001, 2.3 million stents were implanted (more than double the 1998 rate)
A wide range of patients may be considered for percutaneous coronary intervention. It is essential that the benefits and risks of the procedure, as well as coronary artery bypass graft surgery and medical treatment, are discussed with patients (and their families) in detail. They must understand that, although the percutaneous procedure is more attractive than bypass surgery, it has important limitations, including the likelihood of restenosis and potential for incomplete revascularisation compared with surgery. The potential benefits of antianginal drug treatment and the need for risk factor reduction should also be carefully explained.

Clinical risk assessment

Relief of anginal symptoms is the principal clinical indication for percutaneous intervention, but we do not know whether the procedure has the same prognostic benefit as bypass surgery. Angiographic features determined during initial assessment require careful evaluation to determine the likely success of the procedure and the risk of serious complications.

Until recently, the American College of Cardiology and American Heart Association classified anginal lesions into types (and subtypes) A, B, or C based on the severity of lesion characteristics. Because of the ability of stents to overcome many of the complications of percutaneous intervention, this classification has now been superseded by one reflecting low, moderate, and high risk.

Successful percutaneous intervention depends on adequate visualisation of the target stenosis and its adjacent arterial branches. Vessels beyond the stenosis may also be important because of the potential for collateral flow and myocardial support if the target vessel were to occlude abruptly. Factors that adversely affect outcome include increasing age, comorbid disease, unstable angina, pre-existing heart or renal failure, previous myocardial infarction, diabetes, a large area of myocardium at risk, degree of collateralisation, and multivessel disease.

Preparation for intervention

Patients must be fully informed of the purpose of the procedure as well as its risks and limitations before they are asked for their consent. The procedure must always be carried out (or directly supervised) by experienced, high volume operators (> 100 procedures a year) and institutions (> 400 a year).

A sedative is often given before the procedure, as well as aspirin, clopidogrel, and the patient’s usual antianginal drugs. In very high risk cases an intra-aortic balloon pump may be used. A prophylactic temporary transvenous pacemaker wire may be inserted in some patients with pre-existing, high grade conduction abnormality or those at high risk of developing it.

The procedure

For an uncomplicated, single lesion, a percutaneous procedure may take as little as 30 minutes. However, the duration of the procedure and radiation exposure will vary according to the number and complexity of the treated stenoses and vessels.
As with coronary angiography, arterial access (usually femoral but also brachial or radial) under local anaesthesia is required. A guide catheter is introduced and gently engaged at the origin of the coronary artery. The proximal end of the catheter is attached to a Y connector. One arm of this connector allows continuous monitoring of arterial blood pressure. Dampening or “ventricularisation” of this arterial tracing may indicate reduced coronary flow because of over-engagement of the guide catheter, catheter tip spasm, or a previously unrecognised ostial lesion. The other arm has an adjustable seal, through which the operator can introduce the guidewire and balloon or stent catheter once the patient has been given heparin as an anticoagulant. A glycoprotein IIb/IIIa inhibitor, which substantially reduces ischaemic events during percutaneous coronary intervention, may also be given.

Visualised by means of fluoroscopy and intracoronary injections of contrast medium, a soft tipped, steerable guidewire (usually 0.014” (0.36 mm) diameter) is passed down the coronary artery, across the stenosis, and into a distal branch. A balloon or stent catheter is then passed over the guidewire and positioned at the stenosis. The stenosis may then be stented directly or dilated before stenting. Additional balloon dilatation may be necessary after deployment of a stent to ensure its full expansion.

Balloon inflation inevitably stops coronary blood flow, which may induce angina. Patients usually tolerate this quite well, especially if they have been warned beforehand. If it becomes severe or prolonged, however, an intravenous opiate may be given. Ischaemic electrocardiographic changes are often seen at this time, although they are usually transient and return to baseline once the balloon is deflated (usually after 30-60 seconds). During the procedure, it is important to talk to the patient (who may be understandably apprehensive) to let him or her know what is happening, as this encourages a good rapport and cooperation.

Recovery
After the procedure the patient is transferred to a ward where close monitoring for signs of ischaemia and haemodynamic instability is available. If a femoral arterial sheath was used, it may be removed when the heparin effect has declined to an acceptable level (according to unit protocols). Arterial sealing devices have some advantages over manual compression: they permit immediate sheath removal and haemostasis, are more comfortable for patients, and allow early mobilisation and discharge. However, they are not widely used as they add considerably to the cost of the procedure.

After a few hours, the patient should be encouraged to gradually increase mobility, and in uncomplicated cases discharge is scheduled for the same or the next day. Before discharge, the arterial access site should be examined and the patient advised to seek immediate medical advice if bleeding or chest pain (particularly at rest) occurs. Outpatient follow up and drug regimens are provided, as well as advice on modification of risk factors and lifestyle.

Complications and sequelae
Complications are substantially lower in centres where large numbers of procedures are carried out by adequately trained and experienced operators. Major complications are uncommon and include death (0.2% but higher in high risk cases), acute myocardial infarction (1%) which may require emergency coronary artery bypass surgery, embolic stroke (0.5%), cardiac tamponade (0.5%), and systemic bleeding (0.5%).
Minor complications are more common and include allergy to the contrast medium and nephropathy and complications of the access site (bleeding, haematoma, and pseudoaneurysm).

**Restenosis within a stent**

Although stents prevent restenosis from vascular recoil and remodelling, restenosis within the stent (known as “in-stent restenosis”) due to neointimal proliferation does occur and is the most important late sequel of the procedure. In-stent restenosis is the Achilles’ heel of percutaneous revascularisation and develops within six months of stenting.

Angiographic restenosis rates (>50% diameter stenosis) depend on several factors and are higher in smaller vessels, long and complex stenoses, and where there are coexisting conditions such as diabetes. Approximate rates of angiographic restenosis after percutaneous angioplasty are:

- Angioplasty to de novo lesion in native artery—35%
- Angioplasty and stent to de novo lesion in native artery—25%
- Angioplasty and stent to restenotic lesion in native artery—20%
- Angioplasty and stent to successfully recanalised chronic total occlusion—30%
- Angioplasty to de novo lesion in vein graft—60%
- Angioplasty and stent to de novo lesion in vein graft—30%.

It should be noted that angiographically apparent restenoses do not always lead to recurrent angina (clinical restenosis). In some patients only mild anginal symptoms recur, and these may be well controlled with antianginal drugs, thereby avoiding the need for further intervention.

Using repeat percutaneous angioplasty alone to re-dilate in-stent restenosis results in a high recurrence of restenosis (60%). Various other methods, such as removing restenotic tissue by means of atherectomy or a laser device or re-dilating with a cutting balloon, are being evaluated. Another method is brachytherapy, which uses a special intracoronary catheter to deliver a source of β or γ radiation. It significantly reduces further in-stent restenosis, but it has limitations, including late thrombosis and new restenosis at the edges of the radiation treated segments, giving rise to a “candy wrapper” appearance.

**Diagrammatic representation of the Novoste Beta Cath system used for vascular brachytherapy.** Pre-dilatation of the in-stent restenosis with a balloon catheter is usual and is followed by positioning of the radiation source train, containing strontium-90, at the site for less than 5 minutes. The cutting balloon catheter. The longitudinal cutting blades are exposed only during balloon inflation (top left). In this case (top right) a severe ostial in-stent restenosis in the right coronary artery (arrow) was dilated with a short cutting balloon (bottom left), and a good angiographic result was obtained (arrow, bottom right).

Focal in-stent restenosis. A 2.0 mm stent had been deployed six months earlier. After recurrence of angina, angiography showed focal in-stent restenosis (arrow, top left). This was confirmed with intravascular ultrasound (top right), which also revealed that the stent was underexpanded. The stent was further expanded with a balloon catheter, with a good angiographic result (arrow, bottom left) and an increased lumen diameter to 2.7 mm (bottom right).

**Angiogram showing late “candy wrapper” edge effect (arrows) because of new restenosis at the edges of a segment treated by brachytherapy.**
Drug eluting, coated stents
Coated stents contain drugs that inhibit new tissue growth within the sub-intima and are a promising new option for preventing or treating in-stent restenosis. Sirolimus (an immunosuppressant used to prevent renal rejection which inhibits smooth muscle proliferation and reduces intimal thickening after vascular injury), paclitaxel (the active component of the anticancer drug taxol), everolimus, ABT-578, and tacrolimus are all being studied, as are other agents. Although long term data and cost benefit analyses are not yet available, it seems probable that coated stents will be commonly used in the near future.

Occupation and driving
Doctors may be asked to advise on whether a patient is “fit for work” or “recovered from an event” after percutaneous coronary intervention. “Fitness” depends on clinical factors (level of symptoms, extent and severity of coronary disease, left ventricular function, stress test result) and the nature of the occupation, as well as statutory and non-statutory fitness requirements. Advisory medical standards are in place for certain occupations, such as in the armed forces and police, railwaymen, and professional divers. Statutory requirements cover the road, marine, and aviation industries and some recreational pursuits such as driving and flying.

Patients often ask when they may resume driving after percutaneous coronary intervention. In Britain, the Driver and Vehicle Licensing Agency recommends that group 1 (private motor car) licence holders should stop driving when anginal symptoms occur at rest or at the wheel. After percutaneous coronary intervention, they should not drive for a week. Drivers holding a group 2 licence (lorries or buses) will be disqualified from driving once the diagnosis of angina has been made, and for at least six weeks after percutaneous coronary intervention. Re-licensing may be permitted provided the exercise test requirement (satisfactory completion of nine minutes of the Bruce protocol while not taking β blockers) can be met and there is no other disqualifying condition.

The diagram of the Angio-Seal device is used with permission of St Jude Medical, Minnetonka, Minnesota, USA. The angiogram showing the “candy wrapper” effect is reproduced with permission of R Waksman, Washington Hospital Center, and Martin Dunitz, London.

Competing interests: None declared.

Further reading


• Kimmel SE, Berlin JA, Laskey WK. The relationship between coronary angioplasty procedure volume and major complications. JAMA 1995;274:1137-42


The incidence of restenosis is particularly high with percutaneous revascularisation of small vessels. A small diseased diagonal artery (arrows, top left) in a 58 year old patient with limiting angina was stented with a sirolimus coated Cypher stent (red line, top right). After six months, no restenosis was present (left), and the patient remained asymptomatic.
4 Chronic stable angina: treatment options

Laurence O’Toole, Ever D Grech

In patients with chronic stable angina, the factors influencing the choice of coronary revascularisation therapy (percutaneous coronary intervention or coronary artery bypass surgery) are varied and complex. The severity of symptoms, lifestyle, extent of objective ischaemia, and underlying risks must be weighed against the benefits of revascularisation and the patient’s preference, as well as local availability and expertise. Evidence from randomised trials and large revascularisation registers can guide these decisions, but the past decade has seen rapid change in medical treatment, bypass surgery, and percutaneous intervention. Therefore, thought must be given to whether older data still apply to contemporary practice.

Patients with chronic stable angina have an average annual mortality of 2-3%, only twice that of age matched controls, and this relatively benign prognosis is an important consideration when determining the merits of revascularisation treatment. Certain patients, however, are at much higher risk. Predictors include poor exercise capacity with easily inducible ischaemia or a poor haemodynamic response to exercise, angina of recent onset, previous myocardial infarction, impaired left ventricular function, and the number of coronary vessels with significant stenoses, especially when disease affects the left main stem or proximal left anterior descending artery. Although the potential benefits of revascularisation must be weighed against adverse factors, those most at risk may have the most to gain.

Treatment strategies

Medical treatment
Anti-ischaemic drugs improve symptoms and quality of life, but have not been shown to reduce mortality or myocardial infarction. β blockers may improve survival in hypertension, in heart failure, and after myocardial infarction, and so are considered by many to be first line treatment. Nicorandil has recently been shown to reduce ischaemic events and need for hospital admission.

Trials comparing medical treatment with revascularisation predate the widespread use of antiplatelet and cholesterol lowering drugs. These drugs reduce risk, both in patients treated with drugs only and in those undergoing revascularisation, and so may have altered the risk-benefit ratio for a particular revascularisation strategy in some patients.

Coronary artery bypass graft surgery
Coronary artery bypass surgery involves the placement of grafts to bypass stenosed native coronary arteries, while maintaining cerebral and peripheral circulation by cardiopulmonary bypass. The grafts are usually saphenous veins or arteries (principally the left internal mammary artery).

Operative mortality is generally 1-3% but may be much higher in certain subsets of patients. Scoring systems can predict operative mortality based on clinical, investigational, and operative factors. Important developments that have occurred since trials of bypass surgery versus medical treatment were conducted include increased use of arterial grafts (which have much greater longevity than venous grafts), surgery without extracorporeal circulation (“off-pump” bypass), and minimal access surgery.

Major factors influencing risks and benefits of coronary revascularisation

<table>
<thead>
<tr>
<th>Factor</th>
<th>Weighted score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced age</td>
<td>Multiple coronary vessels affected</td>
</tr>
<tr>
<td>Female</td>
<td>Coexisting valve disease</td>
</tr>
<tr>
<td>Severe angina</td>
<td>Impaired left ventricular function</td>
</tr>
<tr>
<td>Smoking</td>
<td>Impaired renal function</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Cerebrovascular or peripheral vascular disease</td>
</tr>
<tr>
<td>Obesity</td>
<td>Recent acute coronary syndrome</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Chronic obstructive airways disease</td>
</tr>
</tbody>
</table>

Risk score for assessing probable mortality from bypass surgery in patients with chronic stable angina

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Weighted score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;60</td>
<td>Score 1 for every 5 years over</td>
</tr>
<tr>
<td>Female sex</td>
<td>1</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>1</td>
</tr>
<tr>
<td>Extracardiac arteriopathy</td>
<td>2</td>
</tr>
<tr>
<td>Neurological dysfunction</td>
<td>2</td>
</tr>
<tr>
<td>Previous cardiac surgery</td>
<td>3</td>
</tr>
<tr>
<td>Serum creatinine &gt; 200UMOL/L</td>
<td>2</td>
</tr>
<tr>
<td>Reduced left ventricular ejection fraction &lt; 30-50%</td>
<td>1 for 30-50%</td>
</tr>
<tr>
<td>Myocardial infarction in past 90 days</td>
<td>2</td>
</tr>
<tr>
<td>Pulmonary artery systolic pressure &gt; 60 mm Hg</td>
<td>2</td>
</tr>
<tr>
<td>Major cardiac procedure as well as bypass surgery</td>
<td>2</td>
</tr>
<tr>
<td>Emergency operation</td>
<td>2</td>
</tr>
</tbody>
</table>

- Total score ≤2 predicts < 1% operative mortality
- Total score of 3-5 predicts 3% operative mortality
- Total score >6 predicts >10% operative mortality

A more detailed assessment with logistic analysis is available at www.euroscore.org and is recommended for assessing high risk patients.
Percutaneous coronary intervention

The main advantages of percutaneous intervention over bypass surgery are the avoidance of the risks of general anaesthesia, uncomfortable sternotomy and saphenous wounds, and complications of major surgery (infections and pulmonary emboli). Only an overnight hospital stay is necessary (and many procedures can be performed as day cases), and the procedure can be easily repeated. The mortality is low (0.2%), and the most serious late complication is restenosis.

Patient suitability is primarily determined by technical factors. A focal stenosis on a straight artery without proximal vessel tortuosity or involvement of major side branches is ideal for percutaneous intervention. Long, heavily calcified stenoses in tortuous vessels or at bifurcations and chronic total occlusions are less suitable. This must be borne in mind when interpreting data from trials of percutaneous intervention and bypass surgery, as only a minority of patients were suitable for both procedures. Nowadays, more and more patients undergo percutaneous intervention, and referral rates for bypass surgery are falling.

Comparative studies of revascularisation strategies

Coronary artery bypass surgery versus medical treatment

In a meta-analysis of seven trials comparing bypass surgery with medical treatment, surgery conferred a survival advantage in patients with severe left main stem coronary disease, three vessel disease, or two vessel disease with severely affected proximal left anterior descending artery. The survival gain was more pronounced in patients with left ventricular dysfunction or a strongly positive exercise test. However, only 10% of trial patients received an internal mammary artery graft, only 25% received antiplatelet drugs, and the benefit of lipid lowering drugs on long term graft patency was not appreciated when these studies were carried out. Furthermore, 40% of the medically treated patients underwent bypass surgery during 10 years of follow up. Thus, these data may underestimate the benefits of surgery compared with medical treatment alone.

In lower risk patients bypass surgery is indicated only for symptom relief and to improve quality of life when medical treatment has failed. Surgery does this effectively, with 95% of patients gaining immediate relief from angina and 75% remaining free from angina after five years. Unfortunately, venous grafts have a median life span of only seven years, and after 15 years only 15% of patients are free from recurrent angina or death or myocardial infarction. However, the increased use of internal mammary artery grafts, which have excellent long term patency (85% at 10 years), has increased postoperative survival and reduced long term symptoms.

Subgroup analysis of mortality benefit from coronary artery bypass surgery compared with medical treatment at 10 years after randomisation for patients with chronic stable angina

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Mean (1.96 SE) increased survival time (months)</th>
<th>P value of difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vessel disease:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 or 2 vessels</td>
<td>1.8 (3.0)</td>
<td>0.25</td>
</tr>
<tr>
<td>3 vessels</td>
<td>5.7 (3.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>Left main stem</td>
<td>19.3 (13.7)</td>
<td>0.005</td>
</tr>
<tr>
<td>Left ventricular function:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>2.3 (2.4)</td>
<td>0.06</td>
</tr>
<tr>
<td>Abnormal</td>
<td>10.6 (6.1)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Exercise test:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>3.3 (4.4)</td>
<td>0.14</td>
</tr>
<tr>
<td>Abnormal</td>
<td>5.1 (3.3)</td>
<td>0.002</td>
</tr>
<tr>
<td>Severity of angina:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCS class 0, I, II</td>
<td>3.3 (2.7)</td>
<td>0.02</td>
</tr>
<tr>
<td>CCS class III, IV</td>
<td>7.3 (4.8)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

CCS=Canadian Cardiovascular Society

Chronic stable angina: treatment options

**Left:** Angiogram of a 10 year old diseased venous graft to the obtuse marginal artery showing proximal aneurysmal dilatation (A) and severe stenosis in middle segment (B). **Right:** Removal of this graft after repeat bypass surgery shows its gross appearance (graft longitudinally opened in right image), with atherosclerosis in a thin walled aneurysm and a small residual lumen.
Percutaneous coronary intervention versus medical treatment

Most percutaneous procedures are undertaken to treat single vessel or two vessel disease, but few randomised controlled trials have compared percutaneous intervention with medical treatment. These showed that patients undergoing the percutaneous procedure derived greater angina relief and took less drugs but required more subsequent procedures and had more complications (including non-fatal myocardial infarction), with no mortality difference. Patients with few symptoms did not derive benefit. Therefore, percutaneous intervention is suitable for low risk patients with one or two vessel disease and poor symptom control with drugs, at a cost of a slightly higher risk of non-fatal myocardial infarction. However, the procedure may not be indicated if symptoms are well controlled.

Percutaneous intervention versus bypass surgery

Single vessel disease

In a meta-analysis by Pocock et al percutaneous intervention in patients with single vessel disease resulted in mortality similar to that found with bypass surgery (3.7% v 3.1% respectively) but a higher rate of non-fatal myocardial infarction (10.1% v 6.1%, P=0.04). Angina was well treated in both groups, but persistence of symptoms was slightly higher with percutaneous intervention. Rates of repeat revascularisation were much higher with percutaneous intervention than bypass surgery.

Multivessel disease

Since comparative trials could recruit only those patients who were suitable for either revascularisation strategy, only 3-7% of screened patients were included. These were predominantly “low risk” patients with two vessel disease and preserved left ventricular function—patients in whom bypass surgery has not been shown to improve survival—and thus it is unlikely that a positive effect in favour of percutaneous intervention would have been detected. The generally benign prognosis of chronic stable angina means that much larger trials would have been required to show significant differences in mortality.

A meta-analysis of data available to the end of 2000 revealed similar rates of death and myocardial infarction with both procedures, but repeat revascularisation rates were higher with percutaneous intervention. The prevalence of appreciable angina was greater with percutaneous intervention at one year, but this difference disappeared at three years.

The nature of percutaneous coronary intervention has changed considerably over the past 10 years, with important developments including stenting and improved antiplatelet drugs. The integrated use of these treatments clearly improves outcomes, but almost all of the revascularisation trials predate these developments.

A more recent trial comparing percutaneous intervention and stenting with bypass surgery in multivessel disease confirmed similar rates of death, myocardial infarction, and stroke at one year, with much lower rates of repeat revascularisation after percutaneous intervention compared with earlier trials. There was also a cost benefit of nearly $3000 (€1875) per patient associated with percutaneous intervention at 12 months. The recent introduction of drug eluting (coated) stents, which seem to reduce substantially the problem of restenosis, is likely to extend the use of percutaneous intervention in multivessel disease over the next few years.

Diabetes

Bypass surgery confers a survival advantage in symptomatic diabetic patients with multivessel disease The BARI trial
revealed a significant difference in five year mortality (21% with percutaneous intervention v 6% with bypass surgery). Similar trends have been found in other large trials. However, the recent RAVEL and SIRIUS studies, in which the sirolimus eluting Cypher stent was compared with the same stent uncoated, showed a remarkable reduction in restenosis rates within the stented segments in diabetic patients (0% v 42% and 18% v 51% respectively). Ongoing trials will investigate this issue further.

Other study data
Large registries of outcomes in patients undergoing revascularisation have the advantage of including all patients rather than the highly selected groups included in randomised trials. The registry data seem to agree with those from randomised trials: patients with more extensive disease fare better with bypass surgery, whereas percutaneous intervention is preferable in focal coronary artery disease.

An unusual observation is that patients screened and considered suitable for inclusion in a trial fared slightly better if they refused to participate than did those who enrolled. The heterogeneous nature of coronary disease means that certain patient subsets will probably benefit more from one treatment than another. The better outcome in the patients who were suitable but not randomised may indicate that cardiologists and surgeons recognise which patients will benefit more from a particular strategy—subtleties that are lost in the randomisation process of controlled trials.

Refractory coronary artery disease
Increasing numbers of patients with coronary artery disease have angina that is unresponsive to both maximal drug treatment and revascularisation techniques. Many will have already undergone multiple percutaneous interventions or bypass surgery procedures, or have diffuse and distal coronary artery disease. In addition to functional limitations, their prognosis may be poor because of impaired ventricular function. Emerging treatments may provide alternative symptomatic improvement for some patients. There is also renewed interest in the potential anti-ischaemic effects of angiotensin converting enzyme inhibitors and the plaque stabilising properties of statins.

The picture showing three completed coronary artery bypass grafts and the pictures of a 10 year old diseased venous graft to the obtuse marginal artery were provided by G Singh, consultant cardiothoracic surgeon, Heath Sciences Centre, Winnipeg, E Pascoe, consultant cardiothoracic surgeon, St Boniface Hospital, Winnipeg, and J Scalfiff, consultant anaesthetist, St Boniface Hospital. The picture of the FilterWire EX distal embolisation protection device was provided by Boston Scientific Corporation, Minneapolis, USA.

Competing interests: None declared.

Chronic stable angina: treatment options

Names of trials
- BARI—Bypass angioplasty revascularisation investigation
- SIRIUS—Sirolimus-coated velocity stent in treatment of patients with de novo coronary artery lesions trial
- RAVEL—Randomised study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions

Emerging treatment options for refractory angina
- Drugs—Analgesics, statins, angiotensin converting enzyme inhibitors, antiplatelet drugs
- Neurostimulation—Interruption or modification of afferent nociceptive signals: transcutaneous electric nerve stimulation (TENS), spinal cord stimulation (SCS)
- Enhanced external counterpulsation—Non-invasive pulmonary compression, improving coronary perfusion and decreasing left ventricular afterload
- Laser revascularisation—Small myocardial channels created by laser beams: tranmyocardial laser revascularisation (TMLR), percutaneous transmyocardial laser revascularisation (PTMLR)
- Therapeutic angiogenesis—Cytokines, vascular endothelial growth factor, and fibroblast growth factor injected into ischaemic myocardium, or adenoviral vector for gene transport to promote neovascularisation
- Percutaneous in situ coronary venous arterialisation (PICVA)—Flow redirection from diseased coronary artery into adjacent coronary vein, causing arterialisation of the vein and retroperfusion into ischaemic myocardium
- Percutaneous in situ coronary artery bypass (PICAB)—Flow redirection from diseased artery into adjacent coronary vein and then rerouted back into the artery after the lesion
- Heart transplantation—May be considered when all alternative treatments have failed

Further reading
5 Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction

Ever D Grech, David R Ramsdale

The term acute coronary syndrome refers to a range of acute myocardial ischaemic states. It encompasses unstable angina, non-ST segment elevation myocardial infarction (ST segment elevation generally absent), and ST segment elevation infarction (persistent ST segment elevation usually present). This article will focus on the role of percutaneous coronary intervention in the management of unstable angina and non-ST segment elevation myocardial infarction; the next article will address the role of percutaneous intervention in ST segment elevation infarction.

Although there is no universally accepted definition of unstable angina, it has been described as a clinical syndrome between stable angina and acute myocardial infarction. This broad definition encompasses many patients presenting with varying histories and reflects the complex pathophysiological mechanisms operating at different times and with different outcomes. Three main presentations have been described—angina at rest, new onset angina, and increasing angina.

Pathogenesis

The process central to the initiation of an acute coronary syndrome is disruption of an atheromatous plaque. Fissuring or rupture of these plaques—and consequent exposure of core constituents such as lipid, smooth muscle, and foam cells—leads to the local generation of thrombin and deposition of fibrin. This in turn promotes platelet aggregation and adhesion and the formation of intracoronary thrombus.

Unstable angina and non-ST segment elevation myocardial infarction are generally associated with white, platelet-rich, and only partially occlusive thrombus. Microthrombi can detach and embolise downstream, causing myocardial ischaemia and infarction. In contrast, ST segment elevation (or Q wave) myocardial infarction has red, fibrin-rich, and more stable occlusive thrombus.

Epidemiology

Unstable angina and non-ST segment elevation myocardial infarction account for about 2.5 million hospital admissions worldwide and are a major cause of mortality and morbidity in Western countries. The prognosis is substantially worse than for chronic stable angina. In-hospital death and re-infarction affect 5-10%. Despite optimal treatment with anti-ischaemic and antithrombotic drugs, death and recurrent myocardial infarction occur in another 5-10% of patients in the month after an acute episode. Several studies indicate that these patients may have a higher long term risk of death and myocardial infarction than do patients with ST segment elevation.

Diagnosis

Unstable angina and non-ST segment elevation myocardial infarction are closely related conditions with clinical presentations that may be indistinguishable. Their distinction depends on whether the ischaemia is severe enough to cause myocardial damage and the release of detectable quantities of elevated markers of myocardial necrosis (troponin T, troponin I, and creatine kinase MB), in patients presenting with acute cardiac chest pain.

Three main presentations of unstable angina

- **Angina at rest**—Also prolonged, usually > 20 minutes
- **Angina of new onset**—At least CCS class III in severity
- **Angina increasing**—Previously diagnosed angina that has become more frequent, longer in duration, or lower in threshold (change in severity by ≥ 1 CCS class to at least CCS class III)

CCS = Canadian Cardiovascular Society
markers of myocyte necrosis. Cardiac troponin I and T are the preferred markers as they are more specific and reliable than creatine kinase or its isoenzyme creatine kinase MB.

An electrocardiogram may be normal or show minor non-specific changes, ST segment depression, T wave inversion, bundle branch block, or transient ST segment elevation that resolves spontaneously or after nitrate is given. Physical examination may exclude important differential diagnoses such as pleuritis, pericarditis, or pneumothorax, as well as revealing evidence of ventricular failure and haemodynamic instability.

Management
Management has evolved considerably over the past decade. As platelet aggregation and thrombus formation play a key role in acute coronary syndrome, recent advances in treatment (such as the glycoprotein IIb/IIIa inhibitors, low molecular weight heparin, and clopidogrel) and the safer and more widespread use of percutaneous coronary intervention have raised questions about optimal management.

As patients with unstable angina or non-ST segment elevation myocardial infarction represent a heterogeneous group with a wide spectrum of clinical outcomes, tailoring treatment to match risk not only ensures that patients who will benefit the most receive appropriate treatment, but also avoids potentially hazardous treatment in those with a good prognosis. Therefore, an accurate diagnosis and estimation of the risk of adverse outcome are prerequisites to selecting the most appropriate treatment. This should begin in the emergency department and continue throughout the hospital admission. Ideally, all patients should be assessed by a cardiologist on the day of presentation.

Medical treatment
Medical treatment includes bed rest, oxygen, opiate analgesics to relieve pain, and anti-ischaemic and antithrombotic drugs. These should be started at once on admission and continued in those with probable or confirmed unstable angina or non-ST segment elevation myocardial infarction. Anti-ischaemic drugs include intravenous, oral, or buccal nitroglycerin, β blockers, and calcium antagonists. Antithrombotic drugs include aspirin, clopidogrel, intravenous unfractionated heparin or low molecular weight heparin, and glycoprotein IIb/IIIa inhibitors.

Conservative versus early invasive strategy
“Conservative” treatment involves intensive medical management, followed by risk stratification by non-invasive means (usually by stress testing) to identify patients who may need coronary angiography. This approach is based on the results of two randomised trials (TIMI IIIB and VANQWISH), which showed no improvement in outcome when an “early invasive” strategy was used routinely, compared with a selective approach.

These findings generated much controversy and have been superseded by more recent randomised trials (FRISC II, TACTICS-TIMI 18, and RITA 3), which have taken advantage of the benefits of glycoprotein IIb/IIIa inhibitors and stents. All three studies showed that an early invasive strategy (percutaneous coronary intervention or coronary artery bypass surgery) produced a better outcome than non-invasive management. TACTICS-TIMI 18 also showed that the benefit of early invasive treatment was greatest in higher risk patients with raised plasma concentrations of troponin T, whereas the outcomes for lower risk patients were similar with early invasive and non-invasive management.

Names of trials
- TIMI IIIB—Thrombolysis in myocardial infarction IIIB
- VANQWISH—Veterans affairs non-Q-wave infarction strategies in hospital
- GUSTO IV ACS—Global use of strategies to open occluded arteries-IV in acute coronary syndromes
- RITA 3—Randomised intervention treatment of angina
- FRISC II—Fast revascularisation during instability in coronary artery disease
- TACTICS-TIMI 18—Treat angina with Aggrastat and determine cost of therapy with an invasive or conservative strategy-thrombolysis in myocardial infarction
Identifying higher risk patients

Identifying patients at higher risk of death, myocardial infarction, and recurrent ischaemia allows aggressive antithrombotic treatment and early coronary angiography to be targeted to those who will benefit. The initial diagnosis is made on the basis of a patient’s history, electrocardiography, and the presence of elevated plasma concentrations of biochemical markers. The same information is used to assess the risk of an adverse outcome. It should be emphasised that risk assessment is a continuous process.

The TIMI risk score

Attempts have been made to formulate clinical factors into a user friendly model. Notably, Antman and colleagues identified seven independent prognostic risk factors for early death and myocardial infarction. Assigning a value of 1 for each risk factor present provides a simple scoring system for estimating risk, the TIMI risk score. It has the advantage of being easy to calculate and has broad applicability in the early assessment of patients.

Applying this score to the results in the TACTICS-TIMI 18 study indicated that patients with a TIMI risk score of ≥3 benefited significantly from an early invasive strategy, whereas those with a score of ≤2 did not. Therefore, those with an initial TIMI score of ≥3 should be considered for early angiography (ideally within 24 hours), with a view to revascularisation by percutaneous intervention or bypass surgery. In addition, any patient with an elevated plasma concentration of troponin marker, ST segment changes, or haemodynamic instability should also undergo early angiography.

Conclusion

The diagnosis of unstable angina or non-ST segment elevation myocardial infarction demands urgent hospital admission and coronary monitoring. A clinical history and examination, 12 lead electrocardiography, and measurement of troponin concentration are the essential diagnostic tools. Bed rest, aspirin, clopidogrel, heparin, antianginal drugs, and opiate analgesics are the mainstay of initial treatment.

Early risk stratification will help identify high risk patients, who may require early treatment with glycoprotein IIb/IIIa inhibitors, angiography, and coronary revascularisation. Those deemed suitable for percutaneous intervention should receive a glycoprotein IIb/IIIa inhibitor and stenting as appropriate. There seems to be little merit in prolonged stabilisation of patients before percutaneous intervention, and an early invasive strategy is generally preferable to a conservative one except for patients at low risk of further cardiac events. This approach will shorten hospital stays, improve acute and long term outcomes, and reduce the need for subsequent intervention.

In the longer term, aggressive modification of risk factors is warranted. Smoking should be strongly discouraged, and statins should be used to lower blood lipid levels. Long term treatment with aspirin, clopidogrel (especially after stenting), β blockers, angiotensin converting enzyme inhibitors, and antihypertensive drugs should also be considered. Anti-ischaeumic drugs may be stopped when ischaemia provocation tests are negative.

The picture of a microthrombus occluding an intramyocardial arteriole was provided by K MacDonald, consultant histopathologist, St Boniface Hospital, Winnipeg.

Competing interests: None declared.

### The seven variables for the TIMI risk score

- Age ≥65 years
- ≥3 risk factors for coronary artery disease
- ≥50% coronary stenosis on angiography
- ST segment change > 0.5 mm
- ≥2 anginal episodes in 24 hours before presentation
- Elevated serum concentration of cardiac markers
- Use of aspirin in 7 days before presentation

### Simplified management pathway for patients with unstable angina or non-ST segment elevation myocardial infarction

<table>
<thead>
<tr>
<th>TIMI risk assessment on presentation (aspirin, clopidogrel, heparin, nitrates, β blockers)</th>
<th>Coronary angiography</th>
<th>Possible glycoprotein IIb/IIIa inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk (TIMI risk score 0-2, negative troponin test)</td>
<td>Discharge</td>
<td>Percutaneous coronary intervention plus glycoprotein IIb/IIIa inhibitor</td>
</tr>
<tr>
<td>Higher risk (TIMI risk score ≥3, positive troponin test, dynamic ST changes, or haemodynamically unstable)</td>
<td>Invasive management</td>
<td>Medical treatment</td>
</tr>
<tr>
<td>Positive</td>
<td>Coronary angiography</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>Stress test</td>
<td></td>
</tr>
</tbody>
</table>

Rates of death from all causes and non-fatal myocardial infarction at 14 days, by TIMI risk score. Note sharp rate increase when score ≥3

<table>
<thead>
<tr>
<th>No of TIMI risk factors present</th>
<th>Death or myocardial infarction at 14 days (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 or 1</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
</tr>
</tbody>
</table>

Further reading

6 Acute coronary syndrome: ST segment elevation myocardial infarction

Ever D Grech, David R Ramsdale

Acute ST segment elevation myocardial infarction usually occurs when thrombus forms on a ruptured atheromatous plaque and occludes an epicardial coronary artery. Patient survival depends on several factors, the most important being restoration of brisk antegrade coronary flow, the time taken to achieve this, and the sustained patency of the affected artery.

Recanalisation

There are two main methods of re-opening an occluded artery: administering a thrombolytic agent or primary percutaneous transluminal coronary angioplasty.

Although thrombolysis is the commonest form of treatment for acute myocardial infarction, it has important limitations: a rate of recanalisation (restoring normal flow) in 90 minutes of only 55% with streptokinase or 60% with accelerated alteplase; a 5-15% risk of early or late reclosure leading to acute myocardial infarction, worsening ventricular function, or death; a 1-2% risk of intracranial haemorrhage, with 40% mortality; and 15-20% of patients with a contraindication to thrombolysis.

Primary angioplasty (also called direct angioplasty) mechanically disrupts the occlusive thrombus and compresses the underlying stenosis, rapidly restoring blood flow. It offers a superior alternative to thrombolysis in the immediate treatment of ST segment elevation myocardial infarction. This differs from sequential angioplasty, when angioplasty is performed after thrombolysis. After early trials of thrombolytic drugs, there was much interest in “adjunctive” angioplasty (angioplasty used as a supplement to successful thrombolysis) as this was expected to reduce recurrent ischaemia and re-infarction. Later studies, however, not only failed to show any advantage, but found higher rates of major haemorrhage and emergency bypass surgery. In contrast, “rescue” (also known as “salvage”) angioplasty, which is performed if thrombolysis fails to restore patency after one to two hours, may confer benefit.

Pros and cons of primary angioplasty

Advantages

Large randomised studies have shown that thrombolysis significantly reduces mortality compared with placebo, and this effect is maintained long term. Primary angioplasty confers

<table>
<thead>
<tr>
<th>Time from admission to recanalisation</th>
<th>Thrombolysis</th>
<th>Rescue angioplasty</th>
<th>Primary angioplasty</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3 hours after start of thrombolysis</td>
<td>55-60%</td>
<td>85%</td>
<td>95%</td>
</tr>
<tr>
<td>Time to start of thrombolysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus 2 hours</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Recanalisation with brisk antegrade flow

Systemic fibrinolysis

Staff and catheter laboratory “burden”

Cost of procedure

Effects of treatment with placebo, thrombolytic drugs, or primary percutaneous coronary intervention (PCI) on mortality, incidence of cerebrovascular events, and incidence of non-fatal re-infarction after acute myocardial infarction in randomised studies. Of the 1% incidence of cerebrovascular events in patients undergoing primary percutaneous intervention, only 0.05% were haemorrhagic. In contrast patients receiving thrombolytic drugs had a 1% incidence of haemorrhagic cerebrovascular events (P=0.0001) and an overall 2% incidence of cerebrovascular events (P=0.0004)
extra benefits in terms of substantial reductions in rates of death, cerebrovascular events, and re-infarction.

The information provided by immediate coronary angiography is valuable in determining subsequent management. Patients with severe three vessel disease, severe left main coronary artery stenosis, or occluded vessels unsuitable for angioplasty can be referred for bypass surgery. Conversely, patients whose arteries are found to have spontaneously recanalised or who have an insignificant infarct related artery may be selected for medical treatment, and thus avoid unnecessary thrombolytic treatment.

Disadvantages
The morbidity and mortality associated with primary angioplasty is operator dependent, varying with the skill and experience of the interventionist, and it should be considered only for patients presenting early (<12 hours after acute myocardial infarction).

Procedural complications are more common than with elective angioplasty for chronic angina, and, even though it is usual to deal only with the occluded vessel, procedures may be prolonged. Ventricular arrhythmias are not unusual on recanalisation, but these generally occur while the patient is still in the catheterisation laboratory and can be promptly treated by intravenous drugs or electrical cardioversion. Right coronary artery procedures are often associated with sinus arrest, atrioventricular block, idioventricular rhythm, and severe hypotension. Up to 5% of patients initially referred for primary angioplasty require urgent coronary artery bypass surgery, so surgical backup is essential if risks are to be minimised.

There are logistical hurdles in delivering a full 24 hour service. Primary angioplasty can be performed only when adequate facilities and experienced staff are available. The time from admission to recanalisation should be less than 60 minutes, which may not be possible if staff are on call from home. However, recent evidence suggests that, even with longer delays, primary angioplasty may still be superior to thrombolysis.

A catheterisation laboratory requires large initial capital expenditure and has substantial running costs. However, in an existing, fully supported laboratory operating at high volume, primary angioplasty is at least as cost effective as thrombolysis.

Primary angioplasty and coronary stents
Although early randomised studies of primary angioplasty showed its clinical effectiveness, outcomes were marred by high rates of recurrent ischaemia (10-15% of patients) and early reinfarction of the affected artery (up to 5%). Consequently, haemodynamic and arrhythmic complications arose, with the need for repeat catheterisation and revascularisation, prolonged hospital stay, and increased costs. Furthermore, restenosis rates in the first six months remained disappointingly high (25-45%), and a fifth of patients required revascularisation.

Although stenting the lesion seemed an attractive answer, it was initially thought that deploying a stent in the presence of thrombus over a ruptured plaque would provoke further thrombosis. However, improvements in stent deployment and advances in adjunctive pharmacotherapy have led to greater technical success. Recent studies comparing primary stenting with balloon angioplasty alone have shown that stented patients have significantly less recurrent ischaemia, reinfarction, and subsequent need for further angioplasty. Economic analysis has shown that, as expected, the initial costs were higher but were offset by lower follow up costs after a year.
However, one study (Stent-PAMI) showed that stenting was associated with a small (but significant) decrease in normal coronary flow and a trend towards increased six and 12 month mortality. This led some to examine the use of adjunctive glycoprotein IIb/IIIa inhibitors as a solution.

**Stenting and glycoprotein IIb/IIIa inhibitors**

The first study (CADILLAC) to examine the potential benefits of glycoprotein IIb/IIIa inhibitors combined with stenting showed that abciximab significantly reduced early recurrent ischaemia and reocclusion due to thrombus formation. There was no additional effect on restenosis or late outcomes compared with stenting alone. The slightly reduced rate of normal coronary flow that had been seen in other studies was again confirmed, but did not translate into a significant effect on mortality.

Another study (ADMIRAL) examined the potential benefit of abciximab when given before (rather than during) primary stenting. Both at 30 days' and six months' follow up, abciximab significantly reduced the composite rate of reinfarction, the need for further revascularisation, and mortality. In addition, abciximab significantly improved coronary flow rates immediately after stenting, which persisted up to six months with a significant improvement in residual left ventricular function.

**Future of primary angioplasty**

Primary stenting is not only safe but, by reducing recurrent ischaemic events, also confers advantages over balloon angioplasty alone. Abciximab treatment seems to further improve flow characteristics, prevents distal thrombo-embolisation, and reduces the need for repeat angioplasty. A strategy of primary stenting in association with abciximab seems to be the current gold standard of care for patients with acute myocardial infarction. Future studies will examine the potential benefit of other glycoprotein IIb/IIIa inhibitors. The question of whether on-site surgical cover is still essential for infarct intervention continues to be debated.

---

**Names of trials**

- **CADILLAC**—Controlled abciximab and device investigation to lower late angioplasty complications
- **ADMIRAL**—Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up
- **Stent-PAMI**—Stent primary angioplasty in myocardial infarction

---

**Further reading**

Cardiogenic shock is the commonest cause of death after acute myocardial infarction. It occurs in 7% of patients with ST segment elevation myocardial infarction and 3% with non-ST segment elevation myocardial infarction.

Cardiogenic shock is a progressive state of hypotension (systolic blood pressure < 90 mm Hg) lasting at least 30 minutes, despite adequate preload and heart rate, which leads to systemic hypoperfusion. It is usually caused by left ventricular systolic dysfunction. A patient requiring drug or mechanical support to maintain a systolic blood pressure over 90 mm Hg can also be considered as manifesting cardiogenic shock. As cardiac output and blood pressure fall, there is an increase in sympathetic tone, with subsequent cardiac and systemic effects—such as altered mental state, cold extremities, peripheral cyanosis, and urine output < 30 ml/hour.

Effects of cardiogenic shock

Cardiac effects
In an attempt to maintain cardiac output, the remaining non-ischaemic myocardium becomes hypercontractile, and its oxygen consumption increases. The effectiveness of this response depends on the extent of current and previous left ventricular damage, the severity of coexisting coronary artery disease, and the presence of other cardiac pathology such as valve disease.

Three possible outcomes may occur:

- Compensation—which restores normal blood pressure and myocardial perfusion pressure
- Partial compensation—which results in a pre-shock state with mildly depressed cardiac output and blood pressure, as well as an elevated heart rate and left ventricular filling pressure
- Shock—which develops rapidly and leads to profound hypotension and worsening global myocardial ischaemia.

Without immediate reperfusion, patients in this group have little potential for myocardial salvage or survival.

Systemic effects
The falling blood pressure increases catecholamine levels, leading to systemic arterial and venous constriction. In time, activation of the renin-aldosterone-angiotensin axis causes further vasoconstriction, with subsequent sodium and water retention. These responses have the effect of increasing left ventricular filling pressure and volume. Although this partly compensates for the decline in left ventricular function, a high left ventricular filling pressure leads to pulmonary oedema, which impairs gas exchange. The ensuing respiratory acidosis exacerbates cardiac ischaemia, left ventricular dysfunction, and intravascular thrombosis.

Time course of cardiogenic shock
The onset of cardiogenic shock is variable. In the GUSTO-I study, of patients with acute myocardial infarction, 7% developed cardiogenic shock—11% on admission and 89% in the subsequent two weeks. Almost all of those who developed cardiogenic shock did so by 48 hours after the onset of symptoms, and their overall 30 day mortality was 57%, compared with an overall study group mortality of just 7%.
Differential diagnosis

Hypotension can complicate acute myocardial infarction in other settings.

Right coronary artery occlusion

An occluded right coronary artery (which usually supplies a smaller proportion of the left ventricular muscle than the left coronary artery) may lead to hypotension in various ways: cardiac output can fall due to vagally mediated reflex venodilatation and bradycardia, and right ventricular dilation may displace the intraventricular septum towards the left ventricular cavity, preventing proper filling.

In addition, the right coronary artery occasionally supplies a sizeable portion of left ventricular myocardium. In this case right ventricular myocardial infarction produces a unique set of physical findings, haemodynamic characteristics, and ST segment elevation in lead V₁,R. When this occurs aggressive treatment is indicated as the mortality exceeds 30%.

Ventricular septal defect, mitral regurgitation, or myocardial rupture

In 10% of patients with cardiogenic shock, hypotension arises from a ventricular septal defect induced by myocardial infarction or severe mitral regurgitation after papillary muscle rupture. Such a condition should be suspected if a patient develops a new systolic murmur, and is readily confirmed by echocardiography—which should be urgently requested. Such patients have high mortality, and urgent referral for surgery may be needed. Even with surgery, the survival rate can be low.

Myocardial rupture of the free wall may cause low cardiac output as a result of cardiac compression due to tamponade. It is more difficult to diagnose clinically (raised venous pressure, pulsus paradoxus), but the presence of haemopericardium can be readily confirmed by echocardiography. Pericardial aspiration often leads to rapid increase in cardiac output, and surgery may be necessary.

Management

The left ventricular filling volume should be optimised, and in the absence of pulmonary congestion a saline fluid challenge of at least 250 ml should be administered over 10 minutes. Adequate oxygenation is crucial, and intubation or ventilation should be used early if gas exchange abnormalities are present. Ongoing hypotension induces respiratory muscle failure, and this is prevented with mechanical ventilation. Antithrombotic treatment (aspirin and intravenous heparin) is appropriate.

Supporting systemic blood pressure

Blood pressure support maintains perfusion of vital organs and slows or reverses the metabolic effects of organ hypoperfusion. Inotropes stimulate myocardial function and increase vascular tone, allowing perfusion pressures to increase. Intra-aortic balloon pump counterpulsation often has a dramatic effect on systemic blood pressure. Inflation occurs in early diastole, greatly increasing aortic diastolic pressure to levels above aortic systolic pressure. In addition, balloon deflation during the start of systole reduces the aortic pressure, thereby decreasing myocardial oxygen demand and forward resistance (afterload).

Reperfusion

Although inotropic drugs and mechanical support increase systemic blood pressure, these measures are temporary and have no effect on long term survival unless they are combined with coronary artery recanalisation and myocardial reperfusion.

Hallmarks of right ventricular infarction

- Rising jugular venous pressure, Kassmaul sign, pulsus paradoxus
- Low output with little pulmonary congestion
- Right atrial pressure > 10 mm Hg and >80% of pulmonary capillary wedge pressure
- Right atrial prominent Y descent
- Right ventricle shows dip and plateau pattern of pressure
- Profound hypoxia with right to left shunt through a patent foramen ovale
- ST segment elevation in lead V₁,R

Main indications and contraindications for intra-aortic balloon pump counterpulsation

Indications

- Cardiogenic shock
- Unstable and refractory angina
- Cardiac support for high risk percutaneous intervention
- Hypoperfusion after coronary artery bypass graft surgery
- Septic shock

Contraindications

- Severe aortic regurgitation
- Abdominal or aortic aneurysm
- Severe aorto-iliac disease or peripheral vascular disease

Diagram of intra-aortic balloon pump (left) and its position in the aorta (right)

Effects of intra-aortic balloon pump during systole and diastole
Thrombolysis is currently the commonest form of treatment for myocardial infarction. However, successful fibrinolysis probably depends on drug delivery to the clot, and as blood pressure falls, so reperfusion becomes less likely. One study (GISSI) showed that, in patients with cardiogenic shock, streptokinase conferred no benefit compared with placebo.

The GUSTO-I investigators examined data on 2200 patients who either presented with cardiogenic shock or who developed it after enrolment and survived for at least an hour after its onset. Thirty day mortality was considerably less in those undergoing early angiography (38%) than in patients with late or no angiography (62%). Further analysis suggested that early angiography was independently associated with a 43% reduction in 30 day mortality.

In the SHOCK trial, patients with cardiogenic shock were treated aggressively with inotropic drugs, intra-aortic balloon pump counterpulsation, and thrombolytic drugs. Patients were also randomised to either coronary angiography plus percutaneous intervention or bypass surgery within six hours, or medical stabilisation (with revascularisation only permitted after 54 hours). Although the 30 day primary end point did not achieve statistical significance, the death rates progressively diverged, and by 12 months the early revascularisation group showed a significant mortality benefit (55%) compared with the medical stabilisation group (70%). The greatest benefit was seen in those aged < 75 years and those treated early (< 6 hours). Given an absolute risk reduction of 15% at 12 months, one life would be saved for only seven patients treated by aggressive, early revascularisation.

Support and reperfusion: impact on survival

Over the past 10 years, specific measures to improve blood pressure and restore arterial perfusion have been instituted. Mortality data collected since the 1970s show a significant fall in mortality in the 1990s corresponding with increased use of combinations of thrombolytic drugs, the intra-aortic balloon pump, and coronary angiography with revascularisation by either percutaneous intervention or bypass surgery. Before these measures, death rates of 80% were consistently observed.

Cardiogenic shock is the commonest cause of death in acute myocardial infarction. Although thrombolysis can be attempted with inotropic support or augmentation of blood pressure with the intra-aortic balloon pump, the greatest mortality benefit is seen after urgent coronary angiography and revascularisation. Cardiogenic shock is a catheter laboratory emergency.


Competing interests: None declared.

Further reading

- White HD. Cardiogenic shock: a more aggressive approach is now warranted. Eur Heart J 2000;21:1897-901

Names of trials

- GISSI—Gruppo Italiano per lo studio della sopravvivenza nell’infarto miocardico
- GUSTO—global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries
- SHOCK—should we emergently revascularize occluded coronaries for cardiogenic shock
The dramatic increase in the use of percutaneous coronary intervention has been possible because of advances in adjunctive pharmacotherapy, which have greatly improved safety. Percutaneous intervention inevitably causes vessel trauma, with disruption of the endothelium and atheromatous plaque. This activates prothrombotic factors, leading to localised thrombosis; this may impair blood flow, precipitate vessel occlusion, or cause distal embolisation. Coronary stents exacerbate this problem as they are thrombogenic. For these reasons, drug inhibition of thrombus formation during percutaneous coronary intervention is mandatory, although this must be balanced against the risk of bleeding, both systemic and at the access site.

Coronary artery thrombosis
Platelets are central to thrombus formation. Vessel trauma during percutaneous intervention exposes subendothelial collagen and von Willebrand factor, which activate platelet surface receptors and induce the initial steps of platelet activation. Further platelet activation ultimately results in activation of platelet glycoprotein IIb/IIIa receptor—the final common pathway for platelet aggregation.

Vascular injury and membrane damage also trigger coagulation by exposure of tissue factors. The resulting thrombin formation further activates platelets and converts fibrinogen to fibrin. The final event is the binding of fibrinogen to activated glycoprotein IIb/IIIa receptors to form a platelet aggregate.

Understanding of these mechanisms has led to the development of potent anticoagulants and antiplatelet inhibitors that can be used for percutaneous coronary intervention. Since the early days of percutaneous transluminal coronary angioplasty, heparin and aspirin have remained a fundamental part of percutaneous coronary intervention treatment. Following the introduction of stents, ticlopidine and more recently clopidogrel have allowed a very low rate of stent thrombosis. More recently, glycoprotein IIb/IIIa receptor antagonists have reduced procedural complications still further and improved the protection of the distal microcirculation, especially in thrombus-containing lesions prevalent in acute coronary syndromes.

Antithrombotic therapy
Unfractionated heparin and low molecular weight heparin

Unfractionated heparin is a heterogeneous mucopolysaccharide that binds antithrombin, which greatly potentiates the inhibition of thrombin and factor Xa.

An important limitation of unfractionated heparin is its unpredictable anticoagulant effect due to variable, non-specific binding to plasma proteins. Side effects include haemorrhage at the access site and heparin induced thrombocytopenia. About 10-20% of patients may develop type I thrombocytopenia, which is usually mild and self-limiting. However, 0.5-3.0% of patients exposed to heparin for longer than five days develop the more serious immune mediated, type II thrombocytopenia, which paradoxically promotes thrombosis by platelet activation.

Adjunctive pharmacology during percutaneous coronary intervention

Aspirin—For all clinical settings
Clopidogrel—For stenting; unstable angina or non-ST segment elevation myocardial infarction
Unfractionated heparin—For all clinical settings
Glycoprotein IIb/IIIa receptor inhibitors
Abciximab—For elective percutaneous intervention for chronic stable angina; unstable angina or non-ST segment elevation myocardial infarction (before and during percutaneous intervention); ST segment elevation myocardial infarction (before and during primary percutaneous intervention)
Eptifibatide—For elective percutaneous intervention for chronic stable angina; unstable angina or non-ST segment elevation myocardial infarction (before and during percutaneous intervention)
Tirofiban—For unstable angina or non-ST segment elevation myocardial infarction (before and during percutaneous intervention)

Comparison of unfractionated heparin and low molecular weight heparin

Unfractionated heparin
Molecular weight—3000-30 000 Da
Mechanism of action—Binds antithrombin and inactivates factor Xa and thrombin equally (1:1)
Pharmacokinetics—Variable binding to plasma proteins, endothelial cells, and macrophages, giving unpredictable anticoagulant effects
Short half life
Reversible with protamine
Laboratory monitoring—Activated clotting time
Cost—Inexpensive

Low molecular weight heparin
Molecular weight—4000-6000 Da
Mechanism of action—Binds antithrombin and inactivates factor Xa more than thrombin (2:1)
Pharmacokinetics—Minimal plasma protein binding and no binding to endothelial cells and macrophages, giving predictable anticoagulant effects
Longer half life
Partially reversible with protamine
Laboratory monitoring—Not required
Cost—10-20 times more expensive than unfractionated heparin
Despite these disadvantages, unfractionated heparin is cheap, relatively reliable, and reversible, with a brief duration of anticoagulant effect that can be rapidly reversed by protamine. It remains the antithrombotic treatment of choice during percutaneous coronary intervention.

For patients already taking a low molecular weight heparin who require urgent revascularisation, a switch to unfractionated heparin is generally recommended. Low molecular weight heparin is longer acting and only partially reversible with protamine. The use of low molecular weight heparin during percutaneous intervention is undergoing evaluation.

**Direct thrombin inhibitors**

These include hirudin, bivalirudin, lepirudin, and argatobran. They directly bind thrombin and act independently of antithrombin III. They bind less to plasma proteins and have a more predictable dose response than unfractionated heparin. At present, these drugs are used in patients with immune-mediated heparin induced thrombocytopenia, but their potential for routine use during percutaneous intervention is being evaluated, in particular bivalirudin.

**Antiplatelet drugs**

**Aspirin**

Aspirin irreversibly inhibits cyclo-oxygenase, preventing the synthesis of prothrombotic thromboxane-A2 during platelet activation. Aspirin given before percutaneous intervention reduces the risk of abrupt arterial closure by 50-75%. It is well tolerated, with a low incidence of serious adverse effects. The standard dose results in full effect within hours, and in patients with established coronary artery disease it is given indefinitely. However, aspirin is only a mild antiplatelet agent and has no apparent effect in 10% of patients. These drawbacks have led to the development of another class of antiplatelet drugs, the thienopyridines.

**Thienopyridines**

Ticlopidine and clopidogrel irreversibly inhibit binding of adenosine diphosphate (ADP) during platelet activation. The combination of aspirin plus clopidogrel or ticlopidine has become standard antiplatelet treatment during stenting in order to prevent thrombosis within the stent. As clopidogrel has fewer serious side effects, a more rapid onset, and longer duration of action, it has largely replaced ticlopidine. The loading dose is 300 mg at the time of stenting or 75 mg daily for three days beforehand. It is continued for about four weeks, until new endothelium covers the inside of the stent. However, the recent CREDO study supports the much longer term (1 year) use of clopidogrel and aspirin after percutaneous coronary intervention, having found a significant (27%) reduction in combined risk of death, myocardial infarction, or stroke.

**Glycoprotein IIb/IIIa receptor inhibitors**

These are potent inhibitors of platelet aggregation. The three drugs in clinical use are abciximab, eptifibatide, and tirofiban. In combination with aspirin, clopidogrel (if a stent is to be deployed), and unfractionated heparin, they further decrease ischaemic complications in percutaneous coronary procedures.

Glycoprotein IIb/IIIa receptor inhibition may be beneficial in elective percutaneous intervention for chronic stable angina; for unstable angina or non-ST segment elevation myocardial infarction, for acute myocardial infarction with ST segment elevation.
**Interventional pharmacotherapy**

*Elective percutaneous intervention for chronic stable angina*

Large trials have established the benefit of abciximab and epifibatide during stenting for elective and urgent percutaneous procedures. As well as reducing risk of myocardial infarction during the procedure and the need for urgent repeat percutaneous intervention by 35-50%, these drugs seem to reduce mortality at one year (from 2.4% to 1% in EPISTENT and from 2% to 1.4% in ESPRIT). In diabetic patients undergoing stenting, the risk of complications was reduced to that of non-diabetic patients.

Although most trials showing the benefits of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention relate to abciximab, many operators use the less expensive epifibatide and tirofiban. However, abciximab seems to be superior to tirofiban, with lower 30 day mortality and rates of non-fatal myocardial infarction and urgent repeat percutaneous coronary intervention or coronary artery bypass graft surgery in a wide variety of circumstances (TARGET study). In the ESPRIT trial epifibatide was primarily beneficial in stenting for elective percutaneous intervention, significantly reducing the combined end point of death, myocardial infarction, and urgent repeat percutaneous procedure or bypass surgery at 48 hours from 9.4% to 6.0%. These benefits were maintained at follow up.

As complication rates are already low during elective percutaneous intervention and glycoprotein IIb/IIIa inhibitors are expensive, many interventionists reserve these drugs for higher risk lesions or when complications occur. However, this may be misguided; ESPRIT showed that epifibatide started at the time of percutaneous intervention was superior to a glycoprotein IIb/IIIa inhibitor started only when complications occurred.

*Unstable angina and non-ST segment elevation myocardial infarction*

The current role of glycoprotein IIb/IIIa inhibitors has been defined by results from several randomised trials. In one group of studies 29,885 patients (largely treated without percutaneous intervention) were randomised to receive a glycoprotein IIb/IIIa inhibitor or placebo. The end point of “30 day death or non-fatal myocardial infarction” showed an overall significant benefit of the glycoprotein IIb/IIIa inhibitor over placebo. Surprisingly, the largest trial (GUSTO IV ACS) showed no benefit with abciximab, which may be partly due to inclusion of lower risk patients. The use of glycoprotein IIb/IIIa inhibitors in all patients with unstable angina and non-ST segment elevation myocardial infarction remains debatable, although the consistent benefit seen with these drugs has led to the recommendation that they be given to high risk patients scheduled for percutaneous coronary intervention.

Another study (CURE) showed that the use of clopidogrel rather than a glycoprotein IIb/IIIa inhibitor significantly reduced the combined end point of cardiovascular death, non-fatal myocardial infarction, or stroke (from 11.4% to 9.3%). Similar benefits were seen in the subset of patients who underwent percutaneous coronary intervention. The impact this study will have on the use of glycoprotein IIb/IIIa inhibitors in this clinical situation remains unclear.

In another group of studies (n=16,770), patients were given a glycoprotein IIb/IIIa inhibitor or placebo immediately before or during planned percutaneous intervention. All showed unequivocal benefit with the active drug. Despite their efficacy, however, some interventionists are reluctant to use glycoprotein IIb/IIIa inhibitors in all patients because of their high costs and reserve their use for high risk lesions or when complications occur.

---

**Composite 30 day end point of death and myocardial infarction for six medical treatment trials of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction**

<table>
<thead>
<tr>
<th>Trial</th>
<th>No of patients</th>
<th>Risk ratio (95% CI)</th>
<th>Placebo (%)</th>
<th>Glycoprotein IIb/IIIa inhibitor (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRISM</td>
<td>3232</td>
<td></td>
<td>7.1</td>
<td>5.8</td>
</tr>
<tr>
<td>PRISM Plus</td>
<td>1915</td>
<td></td>
<td>11.9</td>
<td>10.2</td>
</tr>
<tr>
<td>PARAGON A</td>
<td>2282</td>
<td></td>
<td>11.7</td>
<td>11.3</td>
</tr>
<tr>
<td>PURSUIT</td>
<td>9461</td>
<td></td>
<td>15.7</td>
<td>14.2</td>
</tr>
<tr>
<td>PARAGON B</td>
<td>5165</td>
<td></td>
<td>11.4</td>
<td>10.5</td>
</tr>
<tr>
<td>GUSTO-IV ACS</td>
<td>7800</td>
<td></td>
<td>8.0</td>
<td>8.7</td>
</tr>
<tr>
<td>Total</td>
<td>29855</td>
<td>11.5</td>
<td>10.7</td>
<td></td>
</tr>
</tbody>
</table>

P=0.339 Breslow-Day homogeneity

---

**Composite 30 day end point of death and myocardial infarction for seven trials of glycoprotein IIb/IIIa inhibitors given before or during planned percutaneous coronary intervention for unstable angina and non-ST segment elevation myocardial infarction**

<table>
<thead>
<tr>
<th>Trial</th>
<th>No of patients</th>
<th>Risk ratio (95% CI)</th>
<th>Placebo (%)</th>
<th>Glycoprotein IIb/IIIa inhibitor (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIC</td>
<td>2099</td>
<td></td>
<td>9.6</td>
<td>6.6</td>
</tr>
<tr>
<td>IMPACT-II</td>
<td>4010</td>
<td></td>
<td>8.5</td>
<td>7.0</td>
</tr>
<tr>
<td>EPILOG</td>
<td>2792</td>
<td></td>
<td>9.1</td>
<td>4.0</td>
</tr>
<tr>
<td>CAPTURE</td>
<td>1285</td>
<td></td>
<td>9.0</td>
<td>4.8</td>
</tr>
<tr>
<td>RESTORE</td>
<td>2141</td>
<td></td>
<td>6.3</td>
<td>5.1</td>
</tr>
<tr>
<td>EPISTENT</td>
<td>2399</td>
<td></td>
<td>10.2</td>
<td>5.2</td>
</tr>
<tr>
<td>ESPRIT</td>
<td>2084</td>
<td></td>
<td>10.2</td>
<td>6.3</td>
</tr>
<tr>
<td>Total</td>
<td>16770</td>
<td>8.8</td>
<td>5.6</td>
<td></td>
</tr>
</tbody>
</table>

P<0.014 Breslow-Day homogeneity
Acute ST segment elevation myocardial infarction

In many centres primary percutaneous intervention is the preferred method of revascularisation for acute myocardial infarction. To date, randomised studies have shown that abciximab is the only drug to demonstrate benefit in this setting. The development of low cost alternatives and the potential for combination with other inhibitors of the coagulation cascade may increase the use of glycoprotein IIb/IIIa inhibitors.

Restenosis

Although coronary stents reduce restenosis rates compared with balloon angioplasty alone, restenosis within stents remains a problem. Nearly all systemic drugs aimed at reducing restenosis have failed, and drug eluting (coated) stents may ultimately provide the solution to this problem.

The future

Improvements in adjunctive pharmacotherapy, in combination with changes in device technology, will allow percutaneous coronary intervention to be performed with increased likelihood of acute and long term success and with lower procedural risks in a wider variety of clinical situations. Further refinements in antiplatelet treatment may soon occur with rapidly available bedside assays of platelet aggregation.

Competing interests: None declared.

Names of trials

- CAPTURE—C7E3 antiplatelet therapy in unstable refractory angina
- CREDO—Clopidogrel for the reduction of events during observation
- CURE—Clopidogrel in unstable angina to prevent recurrent events
- EPIC—Evaluation of C7E3 for prevention of ischemic complications
- EPILOG—Evaluation in PTCA to improve long-term outcome with abciximab glycoprotein IIb/IIIa blockade
- EPISTENT—Evaluation of IIb/IIIa platelet inhibitor for stenting
- ESPRIT—Enhanced suppression of the platelet glycoprotein IIb/IIIa receptor using integrilin therapy
- GUSTO IV-ACS—Global use of strategies to open occluded arteries IV in acute coronary syndrome
- IMPACT II—Integrilin to minimize platelet aggregation and coronary thrombosis
- PARAGON—Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in the global organization network
- PRISM—Platelet receptor inhibition in ischemic syndrome management
- PRISM-PLUS—Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms
- PURSUIT—Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy
- RESTORE—Randomized efficacy study of tirofiban for outcomes and restenosis

Further reading

Although most percutaneous interventional procedures involve the coronary arteries, major developments in non-coronary transcatheater cardiac procedures have occurred in the past 20 years. In adults the commonest procedures are balloon mitral valvuloplasty, ethanol septal ablation, and septal defect closure. These problems were once treatable only by surgery, but selected patients may now be offered less invasive alternatives. Carrying out such transcatheter procedures requires supplementary training to that for coronary intervention.

### Balloon mitral valvuloplasty

Acquired mitral stenosis is a consequence of rheumatic fever and is commonest in developing countries. Commisural fusion, thickening, and calcification of the mitral valve leaflets typically occur, as well as thickening and shortening of the chordae tendinae. The mitral valve stenosis leads to left atrial enlargement, which predisposes patients to atrial fibrillation and the formation of left atrial thrombus.

In the 1980s percutaneous balloon valvuloplasty techniques were developed that could open the fused mitral commissures in a similar fashion to surgical commissurotomy. The resulting fall in pressure gradient and increase in mitral valve area led to symptomatic improvement. Today, this procedure is most often performed with the hourglass shaped Inoue balloon. This is introduced into the right atrium from the femoral vein, passed across the atrial septum by way of a septal puncture, and then positioned across the stenosed mitral valve before inflation.

### Patient selection

In general, patients with moderate or severe mitral stenosis (valve area < 1.5 cm²) with symptomatic disease despite optimal medical treatment can be considered for this procedure. Further patient selection relies heavily on transthoracic and transoesophageal echocardiographic findings, which provide structural information about the mitral valve and subvalvar apparatus.

A scoring system for predicting outcomes is commonly used to screen potential candidates. Four characteristics (valve mobility, leaflet thickening, subvalvar thickening, and calcification) are each graded 1 to 4. Patients with a score of ≤ 8 are more likely to have to have a good result than those with scores of > 8. Thus, patients with pliable, non-calcified valves and minimal fusion of the subvalvar apparatus achieve the best immediate and long term results.

Relative contraindications are the presence of pre-existing significant mitral regurgitation and left atrial thrombus. Successful balloon valvuloplasty increases valve area to > 1.5 cm² without a substantial increase in mitral regurgitation, resulting in significant symptomatic improvement.

### Complications

The major procedural complications are death (1%), haemopericardium (usually during transseptal catheterisation) (1%), cerebrovascular embolisation (1%), severe mitral regurgitation (due to a torn valve cusp) (2%), and atrial septal defect (although this closes or decreases in size in most patients) (10%). Immediate and long term results are similar to those with surgical valvotomy, and balloon valvuloplasty can be repeated if commisural restenosis (a gradual process with an incidence of 30-40% at 6-8 years) occurs.
In patients with suitable valvar anatomy, balloon valvuloplasty has become the choice of method for mitral stenosis, delaying the need for surgical intervention. It may also be of particular use in those patients who are at high risk of surgical intervention (because of pregnancy, age, or coexisting pulmonary or renal disease).

In contrast, balloon valvuloplasty for adult aortic stenosis is associated with high complication rates and poor outcomes and is only rarely performed.

Ethanol septal ablation

Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is a disease of the myocytes caused by mutations in any one of 10 genes encoding various components of the sarcomeres. It is the commonest genetic cardiovascular disease, being inherited as an autosomal dominant trait and affecting about 1 in 500 of the population. It has highly variable clinical and pathological presentations.

It is usually diagnosed by echocardiography and is characterised by the presence of unexplained hypertrophy in a non-dilated left ventricle. In a quarter of cases septal enlargement may result in substantial obstruction of the left ventricular outflow tract. This is compounded by Venturi suction movement of the anterior mitral valve leaflet during ventricular systole, bringing it into contact with the hypertrophied septum. The systolic anterior motion of the anterior mitral valve leaflet also causes mitral regurgitation.

Treatment
Although hypertrophic cardiomyopathy is often asymptomatic, common symptoms are dyspnoea, angina, and exertional syncope, which may be related to the gradient in the left ventricular outflow tract. The aim of treatment of symptomatic patients is to improve functional disability, reduce the extent of obstruction of the left ventricular outflow tract, and improve diastolic filling. Treatments include negatively inotropic drugs such as β blockers, verapamil, and disopyramide. However, 10% of symptomatic patients fail to respond to drugs, and surgery—ventricular myectomy (which usually involves removal of a small amount of septal muscle) or ethanol septal ablation—can be considered.

The objective of ethanol septal ablation is to induce a localised septal myocardial infarction at the site of obstruction of the left ventricular outflow tract. The procedure involves threading a small balloon catheter into the septal artery supplying the culprit area of septum. Echocardiography with injection of an echocontrast agent down the septal artery allows the appropriate septal artery to be identified and reduces the number of unnecessary ethanol injections.

Once the appropriate artery is identified, the catheter balloon is inflated to completely occlude the vessel, and a small amount of dehydrated ethanol is injected through the central lumen of the catheter into the distal septal artery. This causes immediate vessel occlusion and localised myocardial infarction. The infarct reduces septal motion and thickness, enlarges the left ventricular outflow tract, and may decrease mitral valve systolic anterior motion, with consequent reduction in the gradient of the left ventricular outflow tract. Over the next few months the infarcted septum undergoes fibrosis and shrinkage, which may result in further symptomatic improvement.

The procedure is performed under local anaesthesia with sedation as required. Patients inevitably experience chest discomfort during ethanol injection, and treatment with intravenous opiate analgesics is essential. Patients are usually discharged after four or five days.

Characteristics of hypertrophic cardiomyopathy

Anatomical—Ventricular hypertrophy of unknown cause, usually with disproportionate involvement of the interventricular septum
Physiological—Well preserved systolic ventricular function, impaired diastolic relaxation
Pathological—Extensive disarray and disorganisation of cardiac myocytes and increased interstitial collagen

Echocardiogram showing anterior mitral valve leaflet (AMVL) and septal contact (*** during ventricular systole. Note marked left ventricular (LV) free wall and ventricular septal (VS) hypertrophy. Inversion of an echocontrast agent down the septal artery results in an area of septal echo-brightness (dotted line). (LA-left atrium, AoV-aortic valve)

Angiograms showing ethanol septal ablation. The first septal artery (S1, top left) is occluded with a balloon catheter (top right) before ethanol injection. This results in permanent septal artery occlusion (bottom) and a localised septal myocardial infarction. (LAD-left anterior descending artery, TPW—temporary pacemaker wire)
Complications
Heart block is a frequent acute complication, so a temporary pacing electrode is inserted via the femoral vein beforehand and is usually left in situ for 24 hours after the procedure, during which time the patient is monitored.

The main procedural complications are persistent heart block requiring a permanent pacemaker (10%), coronary artery dissection and infarction requiring immediate coronary artery bypass grafting (2%), and death (1-2%). The procedural mortality and morbidity is similar to that for surgical myectomy, as is the reduction in left ventricular outflow tract gradient. Surgery and ethanol septal ablation have not as yet been directly compared in randomised studies.

Septal defect closure
Atrial septal defects
Atrial septal defects are congenital abnormalities characterised by a structural deficiency of the atrial septum and account for about 10% of all congenital cardiac disease. The commonest atrial septal defects affect the ostium secundum (in the fossa ovalis), and most are suitable for transcatheter closure. Although atrial septal defects may be closed in childhood, they are the commonest form of congenital heart disease to become apparent in adulthood.

Diagnosis is usually confirmed by echocardiography, allowing visualisation of the anatomy of the defect and Doppler estimation of the shunt size. The physiological importance of the defect depends on the duration and size of the shunt, as well as the response of the pulmonary vascular bed. Patients with significant shunts (defined as a ratio of pulmonary blood flow to systemic blood flow > 1.5) should be considered for closure when the diagnosis is made in later life because the defect reduces survival in adults who develop progressive pulmonary hypertension. They may also develop atrial tachyarrhythmias, which commonly precipitate heart failure.

Patients within certain parameters can be selected for transcatheter closure with a septal occluder. In those who are unsuitable for the procedure, surgical closure may be considered.

Patent foramen ovale
A patent foramen ovale is a persistent flap-like opening between the atrial septum primum and secundum which occurs in roughly 25% of adults. With microbubbles injected into a peripheral vein during echocardiography, a patent foramen ovale can be demonstrated by the patient performing and

Indications and contraindications for percutaneous closure of atrial septal defects

<table>
<thead>
<tr>
<th>Indications</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>Clinical</td>
</tr>
<tr>
<td>• If defect causes symptoms</td>
<td>• Sinus venosus defects</td>
</tr>
<tr>
<td>• Associated cerebrovascular embolic event</td>
<td>• Ostium primum defects</td>
</tr>
<tr>
<td>• Divers with neurological decompression sickness</td>
<td>• Pulmonary/systemic flow ratio &gt; 1.5 and reversible pulmonary hypertension</td>
</tr>
<tr>
<td>Anatomical</td>
<td>Anatomical</td>
</tr>
<tr>
<td>• Defects within fossa ovalis (or patent foramen ovale)</td>
<td>• Presence of &gt; 4 mm rim of tissue surrounding defect</td>
</tr>
<tr>
<td>• Defects with stretched diameter &lt; 38 mm</td>
<td>• Ostium secundum defects with other important congenital heart defects requiring surgical correction</td>
</tr>
</tbody>
</table>

Deployment sequence of the Amplatzer septal occluder for closing an atrial septal defect

Micrograph of hypertrophied myocytes in haphazard alignments characteristic of hypertrophic cardiomyopathy. Interstitial collagen is also increased
releasing a prolonged Valsalva manoeuvre. Visualisation of microbubbles crossing into the left atrium reveals a right-to-left shunt mediated by transient reversal of the interatrial pressure gradient. Although a patent foramen ovale (or an atrial septal aneurysm) has no clinical importance in otherwise healthy adults, it may cause paradoxical embolism in patients with cryptogenic transient ischaemic attack or stroke (up to half of whom have a patent foramen ovale), decompression illness in divers, and right-to-left shunting in patients with right ventricular infarction or severe pulmonary hypertension. Patients with patent foramen ovale and paradoxical embolism have an approximate 3.5% yearly risk of recurrent cerebrovascular events.

Secondary preventive strategies are drug treatment (aspirin, clopidogrel, or warfarin), surgery, or percutaneous closure using a dedicated occluding device. A lack of randomised clinical trials directly comparing these options means optimal treatment remains uncertain. However, percutaneous closure offers a less invasive alternative to traditional surgery and allows patients to avoid potential side effects associated with anticoagulants and interactions with other drugs. In addition, divers taking anticoagulants may experience haemorrhage in the ear, sinus, or lung from barotrauma.

**Congenital ventricular septal defects**

Untreated congenital ventricular septal defects that require intervention are rare in adults. Recently, there has been interest in percutaneous device closure of ventricular septal defects acquired as a complication of acute myocardial infarction. However, more experience is necessary to assess the role of this procedure as a primary closure technique or as a bridge to subsequent surgery.

The picture of a stenotic mitral valve and micrograph of myocytes showing hypertrophic cardiomyopathy were provided by C. Litman, consultant histopathologist at the Health Sciences Centre, Winnipeg, Manitoba, Canada. The postmortem picture of a heart with hypertrophic cardiomyopathy was provided by T. Balachandra, chief medical examiner for the Province of Manitoba, Winnipeg. The pictures of Amplatzer occluder devices were provided by AGA Medical Corporation, Minnesota, USA.

Further reading


Amplatzer occluder devices for patent foramen ovale (left) and muscular ventricular septal defects (right)
10 New developments in percutaneous coronary intervention

Julian Gunn, Ever D Grech, David Crossman, David Cumberland

Percutaneous coronary intervention has become a more common procedure than coronary artery bypass surgery in many countries, and the number of procedures continues to rise. In one day an interventionist may treat four to six patients with complex, multivessel disease or acute coronary syndromes. Various balloons, stents, and other devices are delivered by means of a 2 mm diameter catheter introduced via a peripheral artery. The success rate is over 95%, and the risk of serious complications is low. After a few hours patients can be mobilised, and they are usually discharged the same or the next day. Even the spectre of restenosis is now fading.

**Refinements of existing techniques**

The present success of percutaneous procedures is largely because of refinement of our “basic tools” (intracoronary guidewires and low profile balloons), which have greatly contributed to the safety and effectiveness of procedures. However, the greatest technological advance has been in the development of stents. These are usually cut by laser from stainless steel tubes into a variety of designs, each with different radial strength and flexibility. They are chemically etched or electropolished to a fine finish and sometimes coated.

Digital angiography is a great advance over cine-based systems, and relatively benign contrast media have replaced the toxic media used in early angioplasty. Although magnetic resonance and computed tomographic imaging may become useful in the non-invasive diagnosis of coronary artery disease, angiography will remain indispensable to guide percutaneous interventions for the foreseeable future.

**Performance of percutaneous coronary intervention**

**General statistics**

- Success rate of procedure: >95%
- Symptoms improved after procedure: 90%
- Complications: 2%
- Restenosis: 15% (range 5-50%)
- Duration of procedure: 15 minutes-3 hours
- Access point:
  - Femoral artery: 95%
  - Radial or brachial artery: 5%
- Time in hospital after procedure:
  - Overnight: 60%
  - Day case: 20%
  - Longer: 20%
- Intravenous contrast load: 100-800 ml
- X ray dose to patient: 75 Gy/cm²

**Special conditions**

- Success of direct procedure for acute myocardial infarction: >95%
- Success for chronic (>3 month) occluded vessel: 50-75%
- Mortality for procedure in severe cardiogenic shock: 50%
- Restenosis:
  - Vessels <2.5 mm in diameter, >40 mm length: 60%
  - Vessels >3.5 mm diameter, <10 mm length: 5%
- Lesion recurrence later than 6 months after procedure: <5%
- Re-restenosis:
  - After repeat balloon dilatation: 30-50%
  - After brachytherapy: <15%

*Death, myocardial infarction, coronary artery bypass surgery, cerebrovascular accident
†Equivalent to 1-2 computed tomography scans

**New device technology**

Pre-eminent among new devices is the drug eluting (coated) stent, which acts as a drug delivery device to reduce restenosis. The first of these was the sirolimus coated Cypher stent.

<table>
<thead>
<tr>
<th>Interventionsal devices and their uses</th>
<th>Use (% of cases)</th>
<th>Types of lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balloon catheter</td>
<td>100%</td>
<td>Multiple types</td>
</tr>
<tr>
<td>Stent</td>
<td>70-90%</td>
<td>Most types</td>
</tr>
<tr>
<td>Drug eluting stent</td>
<td>0-50%</td>
<td>High risk of restenosis (possibly all)</td>
</tr>
<tr>
<td>Cutting balloon</td>
<td>1-5%</td>
<td>In-stent restenosis, ostial lesions</td>
</tr>
<tr>
<td>Rotablator</td>
<td>1-3%</td>
<td>Calciﬁed, ostial, undilatable lesions</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td>1-3%</td>
<td>In-stent restenosis</td>
</tr>
<tr>
<td>Atherectomy</td>
<td>&lt;1%</td>
<td>Bulky, eccentric, ostial lesions</td>
</tr>
<tr>
<td>Stent graft</td>
<td>&lt;1%</td>
<td>Aneurysm, arteriovenous malformation, perforation</td>
</tr>
<tr>
<td>Thrombectomy</td>
<td>&lt;1%</td>
<td>Visible thrombus</td>
</tr>
<tr>
<td>Laser</td>
<td>&lt;1%</td>
<td>Occlusions, in-stent restenosis</td>
</tr>
<tr>
<td>Distal protection</td>
<td>&lt;1%</td>
<td>Degenerate vein graft</td>
</tr>
</tbody>
</table>

Triple vessel disease is no longer a surgical preserve, and particularly good results are expected with drug eluting stents. In this case, lesions in the left anterior descending (LAD), circumflex (Cx), and right coronary arteries (RCA) (top row) are treated easily and rapidly by stent (S) implantation (bottom row).
Sirolimus is one of several agents that have powerful antimitotic effects and inhibit new tissue growth inside the artery and stent. In a randomised controlled trial (RAVEL) this stent gave a six month restenosis rate of 0% compared with 27% for an uncoated stent of the same design. A later randomised study (SIRIUS) of more complex stenoses (which are more prone to recur) still produced a low rate of restenosis within stented segments (9% vs 36% with uncoated stents), even in patients with diabetes (18% vs 51% respectively). Other randomised studies such as ASPECT and TAXUS II have also shown that coated stents (with the cytotoxic agent paclitaxel) have significantly lower six month restenosis rates than identical uncoated stents (14% vs 39% and 6% vs 20% respectively). By reducing the incidence of restenosis (and therefore recurrent symptoms), drug eluting stents will probably alter the balance of treating coronary artery disease in favour of percutaneous intervention rather than coronary artery bypass surgery. However, coated stents will not make any difference to the potential for percutaneous coronary intervention to achieve acute success in any given lesion; nor do they seem to have any impact on acute and subacute safety.

Although coated stents may, paradoxically, be too effective at altering the cellular response and thus delay the desirable process of re-endothelisation, there is no evidence that this is a clinical problem. However, this problem has been observed with brachytherapy (catheter delivered radiotherapy over a short distance to kill dividing cells); a procedure that is generally reserved for cases of in-stent restenosis. This may lead to late thrombosis as platelets readily adhere to the “raw” surface that results from an impaired healing response. This risk is minimised by prolonged treatment with antiplatelet drugs and avoiding implanting any fresh stents at the time of brachytherapy.

Other energy sources may also prove useful. Sonotherapy (ultrasound) may have potential, less as a treatment in its own right than as a facilitator for gene delivery, and is “benign” in its effect on healthy tissue. Photodynamic therapy (the interaction of photosensitising drug, light, and tissue oxygen) is also being investigated but is still in early development. Laser energy, when delivered via a fine intracoronary wire, is used in a few centres to recanalise blocked arteries.

Names of trials
- ASPECT—Asian paclitaxel-eluting stent clinical trial
- RAVEL—Randomized study with the sirolimus eluting velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions
- SIRIUS—Sirolimus-coated velocity stent in treatment of patients with de novo coronary artery lesions trial
- TAXUS II—Study of the safety and superior performance of the TAXUS drug-eluting stent versus the uncoated stent on de novo lesions

New work practices
Twenty years ago, a typical angioplasty treated one proximally located lesion in a single vessel in a patient with good left ventricular function. Now, it commonly treats two or three vessel disease, perhaps with multiple lesions (some of which may be complex), in patients with impaired left ventricular function, advanced age, and comorbidity. Patients may have undergone
coronary artery bypass surgery and be unsuitable for further heart surgery. Isolated left main stem and ostial right coronary artery lesions, though requiring more experience and variations on traditional techniques, are also no longer a surgical preserve.

**Role of percutaneous coronary intervention**

The role of percutaneous intervention has extended to the point where up to 70% of patients treated have acute coronary syndromes. Trial data now support the use of a combination of a glycoprotein IIb/IIIa inhibitor and early percutaneous intervention to give high risk patients the best long term results. The same applies to acute myocardial infarction, where percutaneous procedures achieve a much higher rate of arterial patency than thrombolytic treatment. Even cardiogenic shock, the most lethal of conditions, may be treated by an aggressive combination of intra-aortic balloon pumping and percutaneous intervention.

The potential for percutaneous procedures to treat a wide range of lesions successfully with low rates of restenosis raises the question of the relative roles of percutaneous intervention and bypass surgery in everyday practice. It takes time to accumulate sufficient trial data to make long term generalisations possible.

Early trials comparing balloon angioplasty with bypass surgery rarely included stents and few patients with three vessel disease (as such disease carried higher risk and percutaneous intervention was not as widely practised as now). The long term results favoured bypass surgery, but theses trials are now outdated. In the second generation of studies, stents were used in percutaneous intervention, improving the results. As in the early studies, surgery and intervention had similarly low complications and mortality. The intervention patients still had more need for repeat procedures because of restenosis than the bypass surgery patients, but the differences were less.

The major drawback of all these studies was an exclusion rate approaching 95%, making the general clinical application of the findings questionable. This was because it was unusual at that time to find patients with multivessel disease who were technically suitable for both methods and thus eligible for inclusion in the trials. Now that drug eluting stents are available, more trials are under way: the balance will now probably tip in favour of percutaneous coronary intervention. Meanwhile, the decision of which treatment is better for a patient at a given time is based on several factors, including the feasibility of percutaneous intervention (which is generally considered as the first option), completeness of revascularisation, comorbidity, age, and the patient’s own preferences.

**Implications for health services**

These issues are likely to pose major problems for health services. Modern percutaneous techniques can be used both to shorten patients’ stay in hospital and to make their treatment minimally hazardous and more comfortable. They can also be used in the first and the last (after coronary artery bypass surgery) stages of a patient’s “ischaemic career.”

On the other hand, for the role of percutaneous coronary intervention in acute infarction to be realised, universal emergency access to this service will be needed. However, most health systems cannot afford this—the main limiting factor being the number of interventionists and supporting staff required to allow a 24 hour rota compatible with legal working hours and the survival of routine elective work.

---

**New developments in percutaneous coronary intervention**

Role of percutaneous coronary intervention

The role of percutaneous intervention has extended to the point where up to 70% of patients treated have acute coronary syndromes. Trial data now support the use of a combination of a glycoprotein IIb/IIIa inhibitor and early percutaneous intervention to give high risk patients the best long term results. The same applies to acute myocardial infarction, where percutaneous procedures achieve a much higher rate of arterial patency than thrombolytic treatment. Even cardiogenic shock, the most lethal of conditions, may be treated by an aggressive combination of intra-aortic balloon pumping and percutaneous intervention.

The potential for percutaneous procedures to treat a wide range of lesions successfully with low rates of restenosis raises the question of the relative roles of percutaneous intervention and bypass surgery in everyday practice. It takes time to accumulate sufficient trial data to make long term generalisations possible.

Early trials comparing balloon angioplasty with bypass surgery rarely included stents and few patients with three vessel disease (as such disease carried higher risk and percutaneous intervention was not as widely practised as now). The long term results favoured bypass surgery, but theses trials are now outdated. In the second generation of studies, stents were used in percutaneous intervention, improving the results. As in the early studies, surgery and intervention had similarly low complications and mortality. The intervention patients still had more need for repeat procedures because of restenosis than the bypass surgery patients, but the differences were less.

The major drawback of all these studies was an exclusion rate approaching 95%, making the general clinical application of the findings questionable. This was because it was unusual at that time to find patients with multivessel disease who were technically suitable for both methods and thus eligible for inclusion in the trials. Now that drug eluting stents are available, more trials are under way: the balance will now probably tip in favour of percutaneous coronary intervention. Meanwhile, the decision of which treatment is better for a patient at a given time is based on several factors, including the feasibility of percutaneous intervention (which is generally considered as the first option), completeness of revascularisation, comorbidity, age, and the patient's own preferences.

Implications for health services

These issues are likely to pose major problems for health services. Modern percutaneous techniques can be used both to shorten patients' stay in hospital and to make their treatment minimally hazardous and more comfortable. They can also be used in the first and the last (after coronary artery bypass surgery) stages of a patient's "ischaemic career."

On the other hand, for the role of percutaneous coronary intervention in acute infarction to be realised, universal emergency access to this service will be needed. However, most health systems cannot afford this—the main limiting factor being the number of interventionists and supporting staff required to allow a 24 hour rota compatible with legal working hours and the survival of routine elective work.
The future for percutaneous coronary intervention

Will percutaneous coronary intervention exist in 20 years time, or, at least, be recognisable as a logical development of today’s procedures? Will balloons and stents still be in use? It is likely that percutaneous procedures will expand further, although some form of biodegradable stent is a possibility. A more “biological” stent might also be able to act as an effective drug or gene reservoir, which may extend local drug delivery into new areas of coronary artery disease. We may find ourselves detecting inflamed (“hot”) plaques with thermography catheters and treating these before they rupture. We may even be able to modify the natural course of coronary artery disease by releasing agents “remotely” (possibly using an external ultrasound trigger) or by injecting an agent that activates the molecular cargo in a stent.

A persistent challenge still limiting the use of percutaneous coronary intervention is that of chronic total occlusions, which can be too tough to allow passage of an angioplasty guidewire. An intriguing technique is percutaneous in situ coronary artery bypass. With skill and ingenuity, a few enthusiasts have anastomosed the stump of a blocked coronary artery to the adjacent cardiac vein under intracoronary ultrasound guidance, thereby using the vein as an endogenous conduit (with reversed flow). This technique may assist only a minority of patients. More practical, we believe, is the concept of drilling through occlusions with some form of external guidance, perhaps magnetic fields.

“Direct” myocardial revascularisation (punching an array of holes into ischaemic myocardium) has had a mixed press over the past decade. Some attribute its effect to new vessel formation, others cite a placebo effect. Although the channels do not stay open, they seem to stimulate new microvessels to grow. Injection of growth factors (vascular endothelial growth factor and fibroblast growth factor) to induce new blood vessel growth also has this effect, and percutaneous injection of these agents into scarred or ischaemic myocardium is achievable. However, we need a more thorough understanding of biological control mechanisms before we can be confident of the benefits of this technology.

Challenges to mechanical revascularisation

Deaths from coronary artery disease are being steadily reduced in the Western world. However, with increasing longevity, it is unlikely that we will see a reduction in the prevalence of its chronic symptoms. More effective primary and secondary prevention; antismoking and healthy lifestyle campaigns; and the widespread use of antplatelet drugs, β blockers, statins, and renin-angiotensin system inhibitors may help prevent, or at least delay, the presentation of symptomatic coronary artery disease. In patients undergoing revascularisation, they are essential components of the treatment “package.” More effective anti-atherogenic treatments will no doubt emerge in the near future to complement and challenge the dramatic progress being made in percutaneous coronary intervention.

Further reading


The coronary artery imaging was provided by John Bowles, clinical specialist radiographer, and Nancy Alford, clinical photographer, Sheffield Teaching Hospitals NHS Trust, Sheffield.

Competing interests: None declared.
Before the 1980s, cardiac electrophysiology was primarily used to confirm mechanisms of arrhythmia, with management mainly by pharmacological means. However, recognised shortcomings in antiarrhythmic drugs spurred the development of non-pharmacological treatments, particularly radiofrequency ablation and implantable defibrillators.

The two major mechanisms by which arrhythmias occur are automaticity and re-entrant excitation. Most arrhythmias are of the re-entrant type and require two or more pathways that are anatomically or functionally distinct but in electrical contact. The conduction in one pathway must also be slowed to a sufficient degree to allow recovery of the other so that an electrical impulse may then re-enter the area of slowed conduction.

**Intracardiac electrophysiological studies**

Intracardiac electrophysiological studies give valuable information about normal and abnormal electrophysiology of intracardiac structures. They are used to confirm the mechanism of an arrhythmia, to delineate its anatomical substrate, and to ablate it. The electrical stability of the ventricles can also be assessed, as can the effects of an antiarrhythmic regimen.

**Atrioventricular conduction**

Electrodes positioned at various sites in the heart can give only limited data about intracardiac conduction during sinus rhythm at rest. “Stressing” the system allows more information to be generated, particularly concerning atrioventricular nodal conduction and the presence of accessory pathways.

By convention, the atria are paced at 100 beats/min for eight beats. The ninth beat is premature (extrastimulus), and the AH (the time between the atrial signal (A) and the His signal (H), which represents atrioventricular node conduction

**Indications for electrophysiological studies**

**Investigation of symptoms**
- History of persistent palpitations
- Recurrent syncope
- Presyncope with impaired left ventricular function

**Interventions**
- Radiofrequency ablation—Accessory pathways, junctional tachycardias, atrial flutter, atrial fibrillation
- Investigation of arrhythmias (narrow and broad complex) with or without radiofrequency ablation
- Assessment or ablation of ventricular arrhythmias

**Contraindications**
- Severe aortic stenosis, unstable coronary disease, left main stem stenosis, substantial electrolyte disturbance
time) is measured. This sequence is repeated with the ninth beat made increasingly premature. In normal atrioventricular nodal conduction, the AH interval gradually increases as the extrastimulus becomes more premature and is graphically represented as the atrioventricular nodal curve. The gradual prolongation of the AH interval (decremental conduction) is a feature that rarely occurs in accessory pathway conduction.

Retrograde ventriculoatrial conduction
Retrograde conduction through the atrioventricular node is assessed by pacing the ventricle and observing conduction back into the atria. The coronary sinus electrode is critically important for this. It lies between the left ventricle and atrium and provides information about signals passing over the left side of the heart. The sequence of signals that pass from the ventricle to the atria is called the retrograde activation sequence.

If an accessory pathway is present, this sequence changes: with left sided pathways, there is an apparent “short circuit” in the coronary sinus with a shorter ventriculoatrial conduction time. This is termed a concealed pathway, as its effect cannot be seen on a surface electrocardiogram. It conducts retrogradely only, unlike in Wolff-Parkinson-White syndrome, where the pathway is bidirectional. Often intracardiac electrophysiological studies are the only way to diagnose concealed accessory pathways, which form the basis for many tachycardias with narrow QRS complexes.

Supraventricular tachycardia
Supraventricular tachycardias have narrow QRS complexes with rates between 150-250 beats/min. The two common mechanisms involve re-entry due to either an accessory pathway (overt as in Wolff-Parkinson-White syndrome or concealed) or junctional re-entry tachycardia.

Accessory pathways
These lie between the atria and ventricles in the atrioventricular ring, and most are left sided. Arrhythmias are usually initiated by an extrasystole or, during intracardiac electrophysiological studies, by an extrastimulus, either atrial or ventricular. The extrasystole produces delay within the atrioventricular node, allowing the signal, which has passed to the ventricle, to re-enter the atria via the accessory pathway. This may reach the atrioventricular node before the next sinus beat arrives but when the atrioventricular node is no longer refractory, thus allowing the impulse to pass down the His bundle and back up to the atrium through the pathway. As ventricular depolarisation is normal, QRS complexes are narrow. This circuit accounts for over 90% of supraventricular tachycardias in

abc of interventional cardiology

38

mechanisms for orthodromic (left) and antedromic (right) atrioventricular re-entrant tachycardia
Wolff-Parkinson-White syndrome. Rarely, the circuit is reversed, and the QRS complexes are broad as the ventricles are fully pre-excited. This rhythm is often misdiagnosed as ventricular in origin.

Treatment—Pathway ablation effects a complete cure by destroying the arrhythmia substrate. Stereable ablation catheters allow most areas within the heart to be reached. The left atrium can be accessed either retrogradely via the aortic valve, by flexing the catheter tip through the mitral valve, or transeptally across the atrial septum. Radiofrequency energy is delivered to the atrial insertion of a pathway and usually results in either a rapid disappearance of pre-excitation on the surface electrocardiogram or, in the case of concealed pathways, normalisation of the retrograde activation sequence. Accessory pathway ablation is 95% successful. Failure occurs from an inability to accurately map pathways or difficulty in delivering enough energy, usually because of positional instability of the catheter. Complications are rare (<0.5%) and are related to vascular access—femoral artery aneurysms or, with left sided pathways, embolic cerebrovascular accidents.

Junctional re-entry tachycardia
This is the commonest cause of paroxysmal supraventricular tachycardia. The atrioventricular nodal curve shows a sudden unexpected prolongation of the AH interval known as a “jump” in the interval. The tachycardia is initiated at or shortly after the jump. The jump occurs because of the presence of two pathways—one slowly conducting but with relatively rapid recovery (the slow pathway), the other rapidly conducting but with relatively slow recovery (the fast pathway)—called duality of atrioventricular nodal conduction. This disparity between conduction speed and recovery allows re-entrance to occur. On a surface electrocardiogram the QRS complexes are narrow, and the P waves are often absent or distort the terminal portion of the QRS complex. These arrhythmias can often be terminated by critically timed atrial or ventricular extrastimuli.

In the common type of junctional re-entry tachycardia (type A) the circuit comprises antegrade depolarisation of the slow pathway and retrograde depolarisation of the fast pathway. Rarely (<5% of junctional re-entry tachycardias) the circuit is reversed (type B). The slow and fast pathways are anatomically separate, with both inputting to an area called the compact atrioventricular node. The arrhythmia can be cured by mapping and ablating either the slow or fast pathway, and overall success occurs in 98% of cases. Irreversible complete heart block requiring a permanent pacemaker occurs in 1–2% of cases, with the risk being higher for fast pathway ablation. Therefore, slow pathway ablation is the more usual approach.

Atrial flutter and atrial fibrillation
Atrial flutter is a macro re-entrant circuit within the right atrium. The critical area of slow conduction lies at the base of the right atrium in the region of the slow atrioventricular nodal pathway. Producing a discrete line of ablation between the tricuspid annulus and the inferior vena cava gives a line of electrical block and is associated with a high success rate in terminating flutter. Flutter responds poorly to standard antiarrhythmic drugs, and ablation carries a sufficiently impressive success rate to make it a standard treatment.

Atrial fibrillation is caused by micro re-entrant wavelets circulating around the great venous structures, or it may be related to a focus of atrial ectopy arising within the pulmonary veins at their junction with the left atrium. The first indication that atrial fibrillation was electrically treatable came from the Maze operation (1990). Electrical dissociation of the atria from the great veins was carried out by surgical excision of the veins
from their insertion sites and then suturing them back. The scarred areas acted as insulation, preventing atrial wave-fronts from circulating within the atria. Similar lines of block can be achieved by catheter ablation within the right and left atria. The results look promising, although this is a difficult, prolonged procedure with a high relapse rate. Of more interest is a sub-group of patients with runs of atrial ectopy, which degenerate to paroxysms of atrial fibrillation. These extrasystoles usually originate from the pulmonary veins, and their ablation substantially reduces the frequency of symptomatic atrial fibrillation. With better understanding of the underlying mechanisms and improved techniques, atrial fibrillation may soon become a completely ablatable arrhythmia.

**Ventricular tachycardia**

Ventricular tachycardia carries a serious adverse prognosis, particularly in the presence of coronary artery disease and impaired ventricular function. Treatment options include drugs, occasional surgical intervention (bypass or arrhythmia surgery), and implantable defibrillators, either alone or in combination. Ventricular tachycardia can be broadly divided into two groups, ischaemic and non-ischaemic. The latter includes arrhythmias arising from the right ventricular outflow tract and those associated with cardiomyopathies.

Since the radiofrequency energy of an ablation catheter is destructive only at the site of the catheter tip, this approach lends itself more to arrhythmias where a discrete abnormality can be described, such as non-ischaemic ventricular tachycardia. In ischaemic ventricular tachycardia, where the abnormal substrate often occurs over a wide area, the success rate is lower.

Ideally, the arrhythmia should be haemodynamically stable, reliably initiated with ventricular pacing, and mapped to a localised area within the ventricle. In many cases, however, this is not possible. The arrhythmia may be unstable after initiation and therefore cannot be mapped accurately. The circuit may also lie deep within the ventricular wall and cannot be fully ablated. However, detailed intracardiac maps can be made with multipolar catheters. A newer approach is the use of a non-contact mapping catheter, which floats freely within the ventricles but senses myocardial electrical circuits.

Although the overall, long term, success rate for radiofrequency ablation of ischaemic ventricular tachycardia is only about 65%, this may increase.

**Conclusion**

The electrophysiological approach to treating arrhythmias has been revolutionised by radiofrequency ablation. Better computerised mapping, improved catheters, and more efficient energy delivery has enabled many arrhythmias to be treated and cured. The ability to ablate some forms of atrial fibrillation and improvement in ablation of ventricular tachycardia is heralding a new age of electrophysiology. Ten years ago it could have been said that electrophysiologists were a relatively benign breed of cardiologists who did little harm but little good either. That has emphatically changed, and it can now be attested that electrophysiologists exact the only true cure in cardiology.

**Further reading**

- Schilling RJ, Peter NS, Davies DW. Feasibility of a non-contact catheter for endocardial mapping of human ventricular tachycardia. *Circulation* 1999;99:2543-52

Competing interests: None declared.

The diagrams showing the mechanisms of orthodromic and anterograde atrioventricular re-entrant tachycardia and of slow-fast atrioventricular nodal re-entrant tachycardia are reproduced from *ABC of Clinical Electrocardiography*, edited by Francis Morris, 2002.
Pacing treatment for tachycardia control has achieved success, notably in supraventricular tachycardia. Pacing termination for ventricular tachycardia has been more challenging, but an understanding of arrhythmia mechanisms, combined with increasingly sophisticated pacemakers and the ability to deliver intracardiac pacing and shocks, have led to success with implantable cardioverter defibrillators.

Mechanisms of pacing termination

There are two methods of pace termination. Underdrive pacing was used by early pacemakers to treat supraventricular and ventricular tachycardias. Extrastimuli are introduced at a constant interval, but at a slower rate than the tachycardia, until one arrives during a critical period, terminating the tachycardia. Because of the lack of sensing of the underlying tachycardia, there is a risk of a paced beat falling on the T wave, producing ventricular fibrillation or ventricular tachycardia, or degenerating supraventricular tachycardias to atrial fibrillation. It is also not particularly successful at terminating supraventricular tachycardia or ventricular tachycardia and is no longer used routinely.

Overdrive pacing is more effective for terminating both supraventricular and ventricular tachycardias. It is painless, quick, effective, and associated with low battery drain of the pacemaker. Implantation of devices for terminating supraventricular tachycardias is now rarely required because of the high success rate of radiofrequency ablation procedures (see previous article). Overdrive pacing for ventricular tachycardia is often successful but may cause acceleration or induce ventricular fibrillation. Therefore, any device capable of pace termination of ventricular tachycardia must also have defibrillatory capability.

Implantable cardioverter defibrillators

Initially, cardioverter defibrillator implantation was a major operation requiring thoracotomy and was associated with 3-5% mortality. The defibrillation electrodes were patches sewn on to the myocardium, and leads were tunnelled subcutaneously to the device, which was implanted in a subcutaneous abdominal pocket. Early devices were large and often shocked patients inappropriately, mainly because these relatively unsophisticated units could not distinguish ventricular tachycardia from supraventricular tachycardia.

Current implantation procedures

Modern implantable cardioverter defibrillators are transvenous systems, so no thoracotomy is required and implantation mortality is about 0.5%. The device is implanted either subcutaneously, as for a pacemaker, in the left or right deltopectoral area, or subpectorally in thin patients to prevent the device eroding the skin.

The ventricular lead tip is positioned in the right ventricular apex, and a second lead can be positioned in the right atrial appendage to allow dual chamber pacing if required and discrimination between atrial and ventricular tachycardias. The ventricular defibrillator lead has either one or two shocking coils. For two-coil leads, one is proximal (usually within the superior vena cava), and one is distal (right ventricular apex).

Changes in implantable cardioverter defibrillators over 10 years (1992-2002). Apart from the marked reduction in size, the implant technique and required hardware have also dramatically improved—from the sternotomy approach with four leads and abdominal implantation to the present two-lead transvenous endocardial approach that is no more invasive than a pacemaker implant.
During implantation the unit is tested under conscious sedation. Satisfactory sensing during sinus rhythm, ventricular tachycardia, and ventricular fibrillation is established, as well as pacing and defibrillatory thresholds. Defibrillatory thresholds should be at least 10 joules less then the maximum output of the defibrillator (about 30 joules).

New developments
An important development is the implantable cardioverter defibrillator’s ability to record intracardiac electrograms. This allows monitoring of each episode of anti-tachycardia pacing or defibrillation. If treatment has been inappropriate, then programming changes can be made with a programming unit placed over the defibrillator site.

Current devices use anti-tachycardia pacing, with low and high energy shocks also available—known as tiered therapy. Anti-tachycardia pacing can take the form of adaptive burst pacing, with cycle length usually about 80-90% of that of the ventricular tachycardia. Pacing bursts can be fixed (constant cycle length) or autodecremental, when the pacing burst accelerates (each cycle length becomes shorter as the pacing train progresses). Should anti-tachycardia pacing fail, low energy shocks are given first to try to terminate ventricular tachycardia with the minimum of pain (as some patients remain conscious despite rapid ventricular tachycardia) and reduce battery drain, thereby increasing device longevity.

With the advent of dual chamber systems and improved diagnostic algorithms, shocking is mostly avoided during supraventricular tachycardia. Even in single lead systems the algorithms are now sufficiently sophisticated to differentiate between supraventricular tachycardia and ventricular tachycardia. There is a rate stability function, which assesses cycle length variability and helps to exclude atrial fibrillation.

Device recognition of tachyarrhythmias is based mainly on the tachycardia cycle length, which can initiate anti-tachycardia pacing or low energy or high energy shocks. With rapid tachycardias, the device can be programmed to give a high energy shock as first line treatment.

Complications
These include infection; perforation, displacement, fracture, or insulation breakdown of the leads; oversensing or undersensing of the arrhythmia; and inappropriate shocks for sinus tachycardia or supraventricular tachycardia. Psychological problems are common, and counselling plays an important role. Regular follow up is required. If antiarrhythmic drugs are taken the potential use of an implantable cardioverter defibrillator is reduced.

Precautions—after patient death the device must be switched off before removal otherwise a severe electric shock can be delivered to the person removing the device. The implanting centre or local hospital should be informed that the patient has died and arrangements can usually be made to turn the ICD off. The device must be removed before cremation.

Driving and implantable cardioverter defibrillators
The UK Driver and Vehicle Licensing Agency recommends that group 1 (private motor car) licence holders are prohibited from driving for six months after implantation of a defibrillator when there have been preceding symptoms of an arrhythmia. If a shock is delivered within this period, driving is withheld for a further six months.

Any change in device programming or antiarrhythmic drugs means a month of abstinence from driving, and all patients must remain under regular review. There is a five year prohibition on driving if treatment or the arrhythmia is associated with incapacity.
Drivers holding a group 2 licence (lorries or buses) are permanently disqualified from driving.

Indications for defibrillator use

Primary prevention
Primary prevention is considered in those who have had a myocardial infarction, depressed left ventricular systolic function, non-sustained ventricular tachycardia, and inducible sustained ventricular tachycardia at electrophysiological studies.

The major primary prevention trials, MADIT and MUSTT, showed that patients with implanted defibrillators had >50% improvement in survival compared with control patients, despite 75% of MADIT control patients being treated with the antiarrhythmic drug amiodarone. A recent trial (MADIT-III) randomised 1292 patients with any history of myocardial infarction and left ventricular dysfunction (ejection fraction <30%) to receive a defibrillator or to continue medical treatment and showed that patients with the device had a 31% reduction in risk of death. Although these results are good news clinically, they raise difficult questions about the potentially crippling economic impact of this added healthcare cost.

Implantation is also appropriate for cardiac conditions with a high risk of sudden death—long QT syndrome, hypertrophic cardiomyopathy, Brugada syndrome, arrhythmogenic right ventricular dysplasia, and after repair of tetralogy of Fallot.

Secondary prevention
Secondary prevention is suitable for patients who have survived cardiac arrest outside hospital or who have symptomatic, sustained ventricular tachycardia. A meta-analysis of studies of implanted defibrillators for secondary prevention showed that they reduced the relative risk of death by 28%, almost entirely due to a 50% reduction in risk of sudden death.

When left ventricular function is impaired and heart failure is highly symptomatic, addition of a third pacing lead in the coronary sinus allows left ventricular pacing and resynchronisation of ventricular contraction. Indications for these new “biventricular” pacemakers include a broad QRS complex (>115-130 ms), left ventricular dilatation, and severe dyspnoea (New York Heart Association class 3). Biventricular pacing improves symptoms and, when combined with an implantable cardioverter defibrillator, confers a significant (40%) mortality benefit (COMPANION study).

Atrial flutter and fibrillation
Pacing to prevent atrial tachycardias, including atrial fibrillation, is presently under intense scrutiny as early results have been favourable. Atrial fibrillation is often initiated by atrial extrasystoles, and attention has focused on pacing to suppress atrial extrasystole, thereby preventing paroxysmal and sustained atrial fibrillation.

Atrial flutter
Termination of atrial flutter is most reliable with burst pacing from the coronary sinus or right atrium and usually requires longer periods of pacing (5-30 s). The shorter the paced cycle length, the sooner the rhythm converts to sinus. Direct conversion to sinus rhythm is achievable with sustained overdrive pacing. However, the success of radiofrequency ablation means these techniques are rarely used.

Atrial fibrillation
Prevention with pacing—Retrospective studies have shown that atrial based pacing results in a reduced burden of atrial fibrillation compared with ventricular based pacing. Pacing the

Guidelines for implanting cardioverter defibrillators

For “primary prevention”
- Non-sustained ventricular tachycardia on Holter monitoring (24 hour electrocardiography)
- Inducible ventricular tachycardia on electrophysiological testing
- Left ventricular dysfunction with an ejection fraction <35% and no worse than class 3 of the NYHA functional classification of heart failure

For “secondary prevention”
- Cardiac arrest due to ventricular tachycardia or ventricular fibrillation
- Spontaneous sustained ventricular tachycardia causing syncope or substantial haemodynamic compromise
- Sustained ventricular tachycardia without syncope or cardiac arrest in patients who have an associated reduction in ejection fraction (<35%) but are no worse than class 3 of NYHA functional classification of heart failure

NYHA = New York Heart Association

Names of trials
- MADIT—Multicenter automatic defibrillator implantation trial
- MUSTT—Multicenter unsustained tachycardia trial
- COMPANION—Comparison of medical therapy, pacing, and defibrillation in chronic heart failure

Chest radiograph showing biventricular pacemaker with leads in the right ventricle, right atrium, and coronary sinus (arrows)

Continuous electrocardiogram showing sinus rhythm with frequent atrial extrasystoles (top) arising from the pulmonary veins degenerating into atrial fibrillation (bottom)
atria at high rates may prevent the conditions required for re-entry and thus prevent atrial fibrillation. Current research is based on triggered atrial pacing, and specific preventive and anti-tachycardia pacing systems are now available for patients with symptomatic paroxysmal atrial tachycardias that are not controlled by drugs. Such devices continually scan the sinus rate and monitor atrial extrasystoles. Right atrial overdrive pacing at 10-29 beats per minute faster than the sinus rate suppresses the frequency of extrasystoles. The pacing rate then slows to allow sinus activity to take over, provided no further extrasystoles are sensed. In some patients atrial fibrillation is initiated during sleep, when the sinus rate is vagally slowed. Resynchronisation (simultaneous pacing at two different atrial sites) in patients with intra-atrial conduction delay may be beneficial. Clinical trials will help answer the question of which form of pacing best prevents atrial fibrillation.

Cardioversion with implantable atrial defibrillators—These are useful in some patients with paroxysmal atrial fibrillation. It is known that rapid restoration of sinus rhythm reduces the risk of protracted or permanent atrial fibrillation. Cardioversion is synchronised to the R wave, and shocks are given between the coronary sinus and right ventricular leads. The problem is that shocks of > 1 joule are uncomfortable, and the mean defibrillation threshold is 3 joules. Thus, sedation is required before each shock.

Future developments
With the development of anti-atrial fibrillation pacing, focal ablation to the pulmonary veins, and flutter ablation, implantable cardioverter defibrillators will be used less often in years to come. The future of device therapy for atrial fibrillation and atrial flutter probably lies in the perfection of radiofrequency ablation and atrial pacing, although there will still be a place for atrioventricular nodal ablation and permanent ventricular pacing in selected patients.

Further reading

Competing interests: TH has been reimbursed by Guidant for attending a conference in 2001.

The figure of implantable cardioverter defibrillators from 1992 and 2002 is supplied by C.M Finlay, CRT coordinator, Guidant Canada Corporation, Toronto.
Interventional paediatric cardiology mainly involves dilatation of stenotic vessels or valves and occlusion of abnormal communications. Many transcatheter techniques—such as balloon dilatation, stent implantation, and coil occlusion—have been adapted from adult practice. Devices to occlude septal defects, developed primarily for children, have also found application in adults.

Basic techniques
Interventional procedures follow a common method. General anaesthesia or sedation is required, and most procedures start with percutaneous femoral access. Haemodynamic measurements and angiograms may further delineate the anatomy or lesion severity. A catheter is passed across the stenosis or abnormal communication. A guidewire is then passed through the catheter to provide a track over which therapeutic devices are delivered. Balloon catheters are threaded directly, whereas stents and occlusion devices are protected or constrained within long plastic sheaths.

Dilatations
Septostomy
Balloon atrial septostomy, introduced by Rashkind 35 years ago, improves mixing of oxygenated and deoxygenated blood in patients with transposition physiology or in those requiring venting of an atrium with restricted outflow. Atrial septostomy outside the neonatal period, when the atrial septum is much tougher, is done by first cutting the atrial septum with a blade.

Balloon valvuloplasty
Pulmonary valve stenosis
Balloon valvuloplasty has become the treatment of choice for pulmonary valve stenosis in all age groups. It relieves the stenosis by tearing the valve, and the resultant pulmonary regurgitation is mild and well tolerated. Surgery is used only for dysplastic valves in patients with Noonan’s syndrome, who have small valve rings and require a patch to enlarge the annulus.

Valvuloplasty is especially useful in neonates with critical pulmonary stenosis, where traditional surgery carried a high mortality. In neonates with the more extreme form of pulmonary atresia with an intact ventricular septum, valvuloplasty can still be done by first perforating the pulmonary valve with a hot wire. Pulmonary valvuloplasty can also alleviate cyanotic spells in patients with tetralogy of Fallot whose pulmonary arteries are not yet large enough to undergo primary repair safely.

Aortic valve stenosis
Unlike in adults, aortic valve stenosis in children (which is non-calcific) is usually treated by balloon dilatation. A balloon size close to the annulus diameter is chosen, as overdilatation (routinely done in pulmonary stenosis) can result in substantial aortic regurgitation. The balloon is usually introduced retrogradely via the femoral artery and passed across the aortic valve. Injection of adenosine, producing brief cardiac standstill during balloon inflation, avoids balloon ejection by powerful left ventricular contraction.
In neonates with critical aortic stenosis and poor left ventricular function the balloon can be introduced in an antegrade fashion, via the femoral vein and across the interatrial septum through the patent foramen ovale. This reduces the risk of femoral artery thrombosis and perforation of the soft neonatal aortic valve leaflets by guidewires. The long term result of aortic valve dilatation in neonates depends on both effective balloon dilatation of the valve and the degree of associated left heart hypoplasia.

Angioplasty
Balloon dilatation for coarctation of the aorta is used for both native and postsurgical coarctation and is the treatment of choice for re-coarctation. Its efficacy in native coarctation depends on the patient's age and whether there is appreciable underdevelopment of the aortic arch. Neonates in whom the ductal tissue forms a sling around the arch have a good initial response to dilatation but a high restenosis rate, probably because of later contraction of ductal tissue. Older patients have a good response to balloon dilatation. However, overdilatation may result in formation of an aneurysm.

Stents
The problems of vessel recoil or dissection have been addressed by the introduction of endovascular stents. This development has been particularly important for patients with pulmonary artery stenoses, especially those who have undergone corrective surgery, for whom repeat surgery can be disappointing. Most stents are balloon expandable and can be further expanded after initial deployment with a larger balloon to keep up with a child's growth.

Results from stent implantation for pulmonary artery stenosis have been good, with sustained increases in vessel diameter, distal perfusion, and gradient reduction. Complications consist of stent misplacement and embolisation, in situ thrombosis, and vessel rupture.

Stents are increasingly used to treat native coarctation in patients over 8 years old. Graded dilatation of a severely stenotic segment over two operations may be required to avoid overdilatation and possible formation of an aneurysm. In patients with pulmonary atresia without true central pulmonary arteries, stenotic collateral arteries can be enlarged by stent implantation (often preceded by cutting balloon dilation) to produce a useful increase in oxygen saturation.

An exciting new advance has been percutaneous valve replacement. A bovine jugular vein valve is sutured to the inner aspect of a large stent, which is crimped on to a balloon delivery system and then expanded into a valveless outflow conduit that has been surgically placed in the right ventricle. Several patients have been treated successfully with this system, although follow up is short.

Oclusions
Transcatheter occlusion of intracardiac and extracardiac communications has been revolutionised by the development of the Amplatzer devices. These are made from a cylindrical Nitinol wire mesh and formed by heat treatment into different shapes. A sleeve with a female thread on the proximal end of the device allows attachment of a delivery cable with a male screw. The attached device can then be pulled and pushed into the loader and delivery sheath respectively. A family of devices has been produced to occlude ostium secundum atrial septal defects, patent foramen ovale, patent ductus arteriosus, and ventricular septal defects.
Atrial septal defects
The Amplatzer atrial septal defect occluder has the shape of two saucers connected by a central stent-like cylinder that varies in diameter from 4 mm to 40 mm to allow closure of both small and large atrial septal defects. Very large secundum atrial septal defects with incomplete margins (other than at the aortic end of the defect) may require a surgically placed patch.

An atrial septal defect is sized with balloon catheters of progressively increasing diameter. An occluder of the correct size is then introduced into the left atrium via a long transvenous sheath. The left atrial disk of the occluder is extruded and pulled against the defect. The sheath is then pulled back to deploy the rest of the device (central waist and right atrial disk) and released after its placement is assessed by transoesophageal echocardiography. The defect is closed by the induction of thrombosis on three polyester patches sewn into the device and is covered by neocardiology within two months. Aspirin is usually given for six months and clopidogrel for 6-12 weeks.

Worldwide, several thousand patients have had their atrial septal defects closed with Amplatzer devices, with high occlusion rates. Complications are unusual and consist of device migration (<1%), transient arrhythmias (1-2%), and, rarely, thrombus formation with cerebral thromboembolism or aortic erosion with tamponade. Transcatheter occlusion is now the treatment of choice for patients with suitable atrial septal defects. Other devices are available, but none has the same applicability or ease of use.

Patent foramen ovale
The Amplatzer atrial septal defect occluder can also be used to treat adults with paradoxical thromboembolism via a patent foramen ovale. The Amplatzer patent foramen ovale occluder has no central stent and is designed to close the flap-valve of the patent foramen ovale. Randomised trials are under way to compare device closure with medical treatment for preventing recurrent thromboembolism.

Patent ductus arteriosus
Although premature babies and small infants with a large patent ductus arteriosus are still treated surgically, most patients with a large patent ductus arteriosus are treated by transcatheter coil occlusion. This technique has been highly successful at closing small defects, but when the minimum diameter is >3 mm multiple and larger diameter coils are required, which prolongs the procedure and increases the risk of left pulmonary artery encroachment. The Amplatzer patent ductus arteriosus plug, which has a mushroom shaped Nitinol frame stuffed with polyester, is used for occluding larger defects. The occlusion rates are close to 100%, higher than published results for surgical ligation.
Ventricular septal defects

Occlusion devices are especially useful for multiple congenital muscular ventricular septal defects, which can be difficult to correct surgically. The Amplatzer occluder device has a drum-like shape and is deployed through long sheaths with relatively small diameter.

Such devices have also been used to occlude perimembranous defects, although in this location they can interfere with aortic valve function. A device with eccentric disks, which should avoid interference with adjacent valves, has recently been introduced. The Amplatzer membranous device has two discs connected by a short cylindrical waist. The device is eccentric, with the left ventricular disc having no margin superiority, where it could come near the aortic valve, and a longer margin inferiortly to hold it on the left ventricular side of the defect. The end screw of the device has a flat portion, which allows it to be aligned with a precurved pusher catheter. This pusher catheter then extrudes the eccentric left ventricular disk from the specially curved sheath with its longer margin orientated inferiorly in the left ventricle. Initial results are promising, particularly for larger infants with haemodynamically important ventricular septal defects.

Transcatheter occlusion has also been used to treat ventricular septal defects in adults who have had a myocardial infarction, and a specific occluder has been introduced. It differs from the infant device in having a 10 mm long central stent to accommodate the thicker adult interventricular septum. Its role in treatment is uncertain, but it offers an alternative for patients who have significant contraindications to surgical closure.

Coil occlusion of unwanted blood vessels

Coil occlusion of unwanted blood vessels (aortopulmonary collateral arteries, coronary artery fistulae, arteriovenous malformations, venous collaterals) is increasingly effective because of improvements in catheter and coil design.

Percutaneous intervention versus surgery

The growth of interventional cardiology has meant that the simpler defects are now dealt with in catheterisation laboratories, and cardiac surgeons are increasingly operating on more complex lesions such as hypoplastic left heart syndrome. More importantly, interventional cardiology can complement the management of these complex patients, resulting in a better outcome for children with congenital heart disease.

Complications such as device embolisation, vessel or chamber perforation, thrombosis, and radiation exposure can be reduced by careful selection of patients and devices, meticulous technique, low dose pulsed fluoroscopy, and, most importantly, operator experience. Further developments in catheter and device design will improve and widen treatment applications.

Competing interests: None declared.

Further reading

Index

Page numbers in **bold** type refer to figures; those in *italics* refer to tables.

abiximab 21, 25, 26, 26, 27, 28
ablation 30–1, 39–40
accessory pathways 37–8, 37, 38, 39–40
acute coronary events 1
acute coronary syndromes 16–18, 16, 19–21
diagnosis 16–17
management 35, 35
adjunctive pharmacotherapy see pharmacotherapy, interventional
AH interval 37–8
Amplatz catheter 3, 3
Amplatz septal defect occluders 31–2, 31, 32, 47, 47, 48
angina 1–4, 5, 15
see also chronic stable angina; unstable angina
angiography 3, 3, 3, 17, 17, 24, 33
angioplasty 5, 5, 6, 6, 19–20
pediatric 46
anterior descending arteries 14, 20, 22, 33, 34
anticoagulant therapy see aspirin; heparin
antiplatelet drugs 5, 7, 25, 26–8
see also abiximab; clopidogrel; glycoprotein IIb/IIIa inhibitors
antithrombotic therapy 23–8, 25
aortic valve stenosis 30, 45–6
arrhythmias 37–40, 37, 41
diagnostic 3–4
implantable devices 41–4
reperfusion 20, 20, 21
arterial grafts 12, 13
arteries
access 9, 9
occlusion 6, 16, 19–21
restenosis 6
stenosis 1, 1, 4, 4, 8, 8, 45–6
aspirin 8, 17, 25, 25, 26
atheroma 1, 1
atheromatous plaques 1, 1, 4
rupture 16, 16, 19–21
ulcerated 35, 36
atrial extrasystoles 43, 44
atrial fibrillation 37, 39–40, 44
atrial flutter 37, 39–40
atrial septal defects 29, 31, 31, 31, 47, 47
atrial septostomy 45, 45
atrial tachycardias 43–4, 43
atrioventricular conduction 37–8, 38
balloon angioplasty 20, 20
balloon catheters 5, 5, 9, 9, 10, 10, 29
balloon dilatation, pediatric 46
balloon pump, intra–aortic 8, 20
balloon septostomy 45, 45
balloon valvuloplasty 29–30, 45–6, 45, 46
barotrauma, arterial 6
blood vessels, coil occlusion 48, 48
brachytherapy 5, 10, 30, 34
bypass surgery 12, 35
chronic stable angina 12, 12, 13, 13, 14–15, 14
emergency 9, 24, 27
percutaneous in situ 36
“candy wrapper” lesions 10, 10
cardiac biochemical markers 16, 17, 18
cardiac tamponade 9, 23, 47
cardiogenic shock 22–4, 22
cardiology referral, priorities for 1, 1
cardiomyopathy, hypertrophic 30–1, 30, 30, 31
cardiovascular disease 1, 1
genesic 30
see also coronary artery disease
cardioverter defibrillators 41–4, 43
catheters
balloon 5, 5, 9, 9, 10, 10, 29
diagnostic 3–4, 3
guide 5, 9, 9
invasive ultrasound (IVUS) 4
non-contact mapping 40, 40
cerebrovascular events 19, 20, 29
chest pain 1
chronic stable angina 12–15
circumflex coronary arteries 14, 33, 34
clinical trials, refusal to participate in 15
clopidogrel 8, 17, 25, 25, 26, 27
coracation of the aorta 46, 46
coil occlusion, transcatheter 47, 47, 48, 48
genital abnormalities 31–2, 45–8
contrast medium 3, 9, 10, 33
coronary arteries, normal 3
coronary artery, right, occlusion 11, 14, 17, 21, 23, 33, 35
coronary artery bypass graft surgery see bypass surgery
coronary artery disease 1–4, 15, 35
coronary sinus electrode signals 38, 38
coronary stents see stents
cutting devices 6, 6, 10, 10
defibrillators 40, 41–4, 43
diabetes
chronic stable angina and 14–15
stents and 10, 27, 34
direct angioplasty see primary angioplasty
Doppler flow wire and pressure wire 4
Index

drills, plaque removal  6, 6

driving fitness  11, 42

electrocardiography  2, 2, 17, 17

intra-cardiac  42, 42
electrophysiology, percutaneous interventional  37–40
endothelial layer, in stents  7, 34
epitifibatide  25, 26, 26, 27
ethanol septal ablation  30–1
exercise tests  2, 2, 13, 13

fitness for work  11
fluoroscopy  9
glycoprotein IIb/IIIa receptor inhibitors  9, 17, 21, 25, 26–8, 26
see also abciximab; epitifibatide; tirofiban
guide catheters  5, 9, 9
guidewires  5, 9, 9

heart block, ablation-induced  31
heparin  9, 17

low molecular weight  25, 26
unfractionated  25–6, 25

“hockey stick” curve  38
hypertrophic cardiomyopathy  30–1, 30, 30, 31
hypotension, in myocardial infarction  22, 23, 24

implantable devices  40, 41–4, 43
internal mammary artery graft  12, 12, 13
intra-aortic balloon pump  22, 23, 23, 23, 24
intravascular ultrasound (IVUS)  4, 4
ischaemia  1–4, 2, 2, 16–17

in percutaneous procedures  9

junctional re-entry tachycardia  37, 39, 39

laser recanalisation  6, 10, 34
left main stem coronary disease  13
left ventricular angiography  3, 3
left ventricular dysfunction  13, 13, 22, 43
left ventricular function, assessment  3, 3
left ventricular hypertrophy  30–1, 30

mitral regurgitation  23, 29, 30
mitral valve stenosis  29–30, 29

mortality rates
cardiogenic shock  22
chronic stable angina  13
glycoprotein IIb/IIIa inhibitors and  27, 27
myocardial infarction  24

multivessel disease  13, 13, 14, 33, 34, 34
myocardial infarction  1–4, 35, 43
non-ST segment elevation  16–18
percutaneous procedures and  9, 27, 27
septal defects caused by  32
ST segment elevation  19–21
myocardial revascularisation  5, 36
myocardial rupture  23, 23

non-contact mapping catheters  40, 40
non-ST segment elevation myocardial infarction  16–18, 27

occlusions, paediatric  46–8
overdrive pacing  41
oxygen need  17, 25, 27

pacemakers  31, 39, 41
biventricular  43, 43
temporary  8, 21

pacing termination  41
paclitaxel coated stents  11, 34
paediatric interventional cardiology  45–8
paradoxical embolism  32, 47
patent ductus arteriosus  47, 47
patent foramen ovale  31–2, 32, 47, 47

patients
high risk  17, 18, 18
refusal to participate in trials  15

percutaneous coronary interventions
adjunctive pharmacotherapy  5, 25, 25, 27
developments  5–7, 33–6
devices  33
indications for  8, 13, 14
procedure  8–11
risk assessment  8
roles of  33
statistics  33

percutaneous interventional electrophysiology
37–40

percutaneous interventions, non-coronary  29–32
pharmacotherapy, interventional  25–8
photodynamic therapy  34

“pigtail” catheter  3–4, 3
platelets  16, 16, 25
see also antiplatelet drugs

primary angioplasty  19–20
pulmonary artery stenosis  46
pulmonary hypertension  31, 32
pulmonary oedema  22, 22
pulmonary valve stenosis  45, 45
pulsus paradoxus  23, 23

radiofrequency ablation  39, 40
radioisotope myocardial perfusion imaging  2–3, 2
recanalisation methods  19, 19
re-endothelialisation, in stents  7, 34
re-entrant arrhythmia  37, 37, 38, 39, 41
refractory coronary artery disease  15
reperfusion  23–4
reperfusion arrhythmias  20, 20, 21
restenosis see arteries; stents
retrograde ventriculotrautal conduction  38
revascularisation  35–6
right coronary artery occlusion  11, 14, 17, 21, 23, 33, 35
right ventricular infarction  23, 23

saphenous vein graft  12, 12, 13, 13
septal ablation, ethanol  30–1
septal artery  30
septal defect closure  31–2, 31, 32, 47, 47, 48
septal enlargement  30, 30
septostomy, balloon atrial  45, 45
sirolimus coated stents  11, 11, 33
smoking  J, 18, 36
sonotherapy  34

stents  5, 6–7, 6, 7, 7, 9, 9, 22
adjunctive pharmacotherapy  25, 27
developments  33–4, 35–6, 35
drug eluting  6, 7, 11, 11, 28, 33–4, 35
paediatric  46, 46
primary angioplasty and  20–1, 21
PTFE coated  6
Index

re-endothelialisation 7, 34
restenosis 10–11, 10, 11, 28, 34
stress echocardiography 2, 2, 2
ST segment elevation myocardial infarction 19–21, 23, 23, 28
supraventricular tachycardia 37, 38–9, 41–2
systolic murmur, cardiogenic shock 23, 23

tachyarrhythmias, implantable devices 41–4
tachycardias 37, 38–9, 40, 43–4, 43
tetralogy of Fallot 45, 46
thienopyridines (antiplatelet drugs) 26
    see also clopidogrel; ticlopidene
thrombin inhibitors 26
thrombocytopenia, heparin–induced 25, 26
thrombolytic drugs 19, 19, 23–4
thrombosis 7, 22, 25–8, 25
    thrombus formation 1, 16, 16, 35
    see also antithrombotic therapy
ticlopidene 25, 26
TIMI risk score 18, 18
tirofiban 25, 26, 26, 27
ultrasonography 4, 4
underdrive pacing 41
unstable angina 16–18, 16, 27
valves see aortic valve; mitral valve; pulmonary valve
valvuloplasty 29–30, 45–6, 45, 46
ventricular septal defects 23, 30–1, 32, 32, 46, 48, 48
ventricular tachycardia 37, 40, 41–2, 43
Wolff-Parkinson-White syndrome 37, 38, 39, 39
x ray, chest pain 2, 3